HENRY SCHEIN® MEDICAL | Rely on Us™

PHARMACEUTICALS

FOR SURGICAL SETTINGS OF CARE

2016 WINTER EDITION

RELY ON US FOR ALL YOUR *Surgical Needs*

#HENRYSCHEIN

To Order, Call: **1-800-P-SCHEIN** 8am–8:30pm (et) • www.henryschein.com/medical

Leading the Way in Surgical Settings of Care

We are pleased to present our sample portfolio of Pharmaceuticals for surgical practitioners—a reference guide designed to provide solutions for your unique surgical needs.

Crash Cart Drugs

All surgical facilities have crash carts — typically one per OR (Operating Room). These constantly need to be checked and refilled due to usage as well as expired meds. Henry Schein offers a Crash Cart Drug checklist found on pages 4 and 5. Also, we only ship crash cart drugs with 6 months or greater expiration dates to ensure these items have an extended shelf life.

Pain Management

Pain Management drugs are utilized in most surgical facilities to help control the pain of their post-op patients. Henry Schein offers a complete selection of both injectable and oral solid pain management drugs, including an extensive line of controlled substances, including Schedule II. You will find a list of the most popular pain management items on pages 8–12.

Controlled Substances (e222)

Schedule II drugs can now be ordered without the hassle and delay of hard copy triplicate forms, through the e222 CSOS system. This system allows registered users to order Schedule II drugs through an easy-to-use online system for prompt processing and delivery. More information on e222 can be found on page 13.

Inventory Management

The Cubex system by Meshura provides a secure, inventory management system for expensive pharmaceuticals and controlled substances. This system can track the amount of individual drugs removed from the storage system by individual identification codes and restrict access to specific personnel for added security. Contact your Henry Schein Sales Consultant for more information. *(See back cover)*

DxRx Solutions

Henry Schein provides unique communication available via toll-free phone, online chat and E-mail to our customers to assist with questions about pharmaceuticals and diagnostics purschased from Henry Schein. The DxRx Solutions Team can provide J Codes, CPT Codes, updates on items in short supply, brand/generic comparisons, copies of package inserts, and much more. Answers to your pharmaceutical and diagnostic questions are only a phone call or E-mail away. See page 27 for more information.

Contrast Media and Diagnostics

Henry Schein provides a full line of contrast media. See pages 21–22 for a list of our most popular items.

Frequently Used Pharmaceuticals

For easy ordering of frequently used items, see our listing broken down by Pre-op, Anesthesia, OR, and Recovery Room on pages 15–17.

Competitive Pricing

With over 6,000 contracts for pharmaceutical items, **Rely on Us** for competitive pricing through both GPO programs and internal contracts that are based on our volume purchasing from supplier partners. We also carry the **NovaPlus** line of private label pharmaceuticals for Novation members enrolled in the Novation pharmacy program.

Product Integrity

Henry Schein operates in full compliance with the Drug Supply Chain Security Act. All of our six distribution centers are VAWD (Verified-Accredited Wholesale Distributors®)—certified by the National Association of Boards of Pharmacy.

TABLE OF CONTENTS

CRASH CART PHARMACEUTICALS

IT'S TIME TO CHECK YOUR EMERGENCY CRASH

Item Code	Description	Strength	Size	Manufacturer
348-1109	Activated Charcoal Powder		1 oz Bottle	Humco
323-0003	Adenocard® (Adenosine)	3 mg/mL	2 mL Syringe	Astellas
323-0004	Adenocard® (Adenosine)	3 mg/mL	4 mL Syringe	Astellas
248-0408	Adenosine	3 mg/mL	2 mL SDV	Akorn
119-9133	Adenosine (Adenocard®)	3 mg/mL	4 mL SDV 10/Pk	Sagent
228-3204	Albuterol Ventolin® HFA Inhaler	0.09 mg/Spray	18 gm Canister	GSK
248-2037	Aminophylline	25 mg/mL	10 mL SDV	Hospira
248-5924	Amiodarone HCl (Cordarone®)	50 mg/mL	3 mL SD Ampule	Hospira
248-0455	Amiodarone HCl/Nexterone® Pre-Mixed IV	150 mg/100 mL	100 mL IV Bag (12/Case)	Baxter
248-0458	Amiodarone HCl/Nexterone® Pre-Mixed IV	360 mg/200 mL	200 mL IV Bag (10/Case)	Baxter
116-0710	Ammonia Inhalant (Aspirol®)		Ampule 10/Pk	X-Gen
104-7773	Aspirin	325 mg (5 gr)	Packet/2 Tablets	Mallinckrodt
248-7959	Atropine Sulfate	0.05 mg/mL (Infant)	5 mL Ansyr Syringe	Hospira
248-7960	Atropine Sulfate	0.1 mg/mL	5 mL Abboject LifeShield Syringe	Hospira
248-4141	Atropine Sulfate	0.1 mg/mL	10 mL Abboject LifeShield Syringe	Hospira
258-0069	Atropine Sulfate	0.4 mg/mL	1 mL SDV	American Regent
248-0537	Atropine Sulfate	1 mg/mL	1 mL SDV	American Regent
113-9785	Butorphanol (Stadol®) – CIV	2 mg/mL	1 mL SDV 10/Bx	Bedford
248-0241	Calcium Chloride	10% (100 mg/mL)	10 mL Abboject LifeShield Syringe	Hospira
248-0663	Calcium Gluconate	10% (100 mg/mL)	10 mL SDV	Fresenius
122-5516	Chloroprocaine HCl (Nesacaine®)	2% (400 mg/20 mL)	20 mL SDVPF 25/Bx	Fresenius
248-7968	Clonidine HCl (Catapres®)	0.1 mg	1 Tablet	Major Pharm
115-7589	Dantrolene Sodium/Dantrium® IV	20 mg/mL	70 mL SDV (6/Box)	JHP Pharma
118-3633	Dantrolene Sodium/Revonto® IV	20 mg/mL	60 mL SDV (6/Box)	US World Med
258-0122	Dexamethasone (Decadron®)	4 mg/mL	5 mL MDV	APP Pharma
248-0160	Dexamethasone (Decadron®)	4 mg/mL	30 mL MDV	Mylan
248-6407	Dextrose	25% (Infant)	10 mL Ansyr Syringe	Hospira
248-0724	Dextrose	50%	50 mL Ansyr Syringe	Hospira
248-6614	Dextrose	50%	50 mL SDV	Hospira
153-9754	Dextrose 5 in Water (D5W)	5%	100 mL IV Bag	Baxter
153-6161	Dextrose 5 in Water (D5W)	5%	250 mL IV Bag	Baxter
258-0265	Dextrose 5 in Water (D5W)	5%	500 mL IV Bag	Hospira
104-6850	Dextrose 5 in Water (D5W)	5%	1000 mL IV Bag	Hospira
153-8920	Dextrose 5% & Sodium Chloride	5%/0.9%	500 mL Bag	Baxter
248-0273	Diazepam (Valium®) – CIV	5 mg/mL	2 mL Carpuject Luer-Lock Syringe	Hospira
248-0274	Diazepam (Valium®) – CIV	5 mg/mL	10 mL MDV	Hospira
119-6366	Diltiazem (Cardizem®)	5 mg/mL 10 mL SDV	10/Box	West Ward
248-1659	Digoxin (Lanoxin®)	0.25 mg/mL	2 mL SD Ampule	Baxter
248-9358	Diphenhydramine (Benadryl®)	50 mg/mL	1 mL Carpuject Luer-Lock Syringe	Hospira
258-5924	Diphenhydramine (Benadryl®)	50 mg/mL	1 mL SDV	Baxter
248-0643	Dobutamine (Dobutrex®)	250 mg/20 mL	20 mL SDV	Hospira
248-0666	Dopamine (Intropine®)	40 mg/mL	5 mL SDV	Hospira
114-7375	Dopamine (Intropine®)	80 mg/mL	5 mL SDV	American Regent
115-5645	Dopamine in 5% Dextrose	400 mg/250 mL (1.6 mg/mL)	250 mL IV Bag	Baxter
248-8166	Epinephrine (Adrenalin® Chloride)	1:10,000 (0.1 mg/mL)	10 mL Abboject Syringe (18G x 3.5")	Hospira
248-8175	Epinephrine (Adrenalin® Chloride)	1:10,000 (0.1 mg/mL)	10 mL Abboject LifeShld Syringe	Hospira
258-9483	Epinephrine (Adrenalin® Chloride)	1:1,000 (1 mg/mL)	5 Pack/1mL Ampules	Hospira
345-1926	Epipen Adult	0.3 mg (Adult)	Pre-filled Syringes (2/Pk)	Mylan
345-3230	Epipen Junior	0.15 mg (Pediatric)	Pre-filled Syringes (2/Pk)	Mylan
277-1282	Epinephrine Auto-injector (Adrenaclick®)	0.3 mg (Adult)	Pre-filled Syringes (2/Pk)	Amedra
277-1281	Epinephrine Auto-injector (Adrenaclick®)	0.15 mg (Pediatric)	Pre-filled Syringes (2/Pk)	Amedra
248-0667	Esmolol HCl (Brevibloc®)	10 mg/mL	10 mL SDV	Mylan
248-0626	Flumazenil (Romazicon®)	0.1 mg/mL	5 mL MDV	West Ward
121-4498	Flumazenil (Romazicon®)	0.1 mg/mL	10 mL MDV	West Ward
181-3332	Furosemide (Lasix®)	10 mg/mL	2 mL SDV	Hospira
248-9356	Furosemide (Lasix®)	10 mg/mL	10 mL Ansyr Syringe	Hospira
123-6512	GlucaGen® Diagnostic Kit (glucagon)	1 mg (1 Unit)	Kit=vial,GlucaGen+vial, Strl Water	BI
375-8394	Heparin Sodium Porcine	1,000 U/mL 1 mL MDV	25/Pk	APP Pharma
248-0407	Hydralazine HCl (Apresoline®)	20 mg/mL	1 mL SDV	APP Pharma
123-5472	Insta-Glucose® Gel	40%	31 gm Tube	Valeant
228-3451	Isuprel® (Isoproterenol HCl)	1:5,000 (0.2 mg/mL)	1 mL SD Ampule 25/Pk	Hospira
258-9639	Ketorolac Tromethamine (Toradol®)	30 mg/mL	1 mL SDV IM/IV	Hospira
840-8589	Labetalol HCl (Trandate®)	5 mg/mL	20 mL MDV	Hospira
258-8050	Lactated Ringers Solution		500 mL Bag	Hospira

CART'S INVENTORY AND EXPIRATION DATES!

Item Code	Description	Strength	Size	Manufacturer
104-6857	Lactated Ringers Solution in Dextrose 5/Water	5%	1000 mL Bag	Hospira
248-7963	Levophed® (Norepinephrine Bitartrate)	1 mg/mL	4 mL SD Ampule	Hospira
248-0238	Lidocaine HCl (Xylocaine®)	1% (10 mg/mL)	5 mL Abboject LifeShield Syringe	Hospira
258-7008	Lidocaine HCl (Xylocaine®)	1% (10 mg/mL)	20 mL MDV	Hospira
248-3812	Lidocaine HCl (Xylocaine®)	2% (20 mg/mL)	5 mL Abboject LifeShield Syringe	Hospira
248-8012	Lidocaine HCl (Xylocaine®) – Cardiac	2% (20 mg/mL)	5 mL Ansyr Syringe	Hospira
248-0235	Lidocaine HCl (Xylocaine®)	2% (20 mg/mL)	5 mL SDV	Hospira
258-0603	Lidocaine HCl (Xylocaine®)	2% (20 mg/mL)	20 mL MDV	Hospira
153-6016	Lidocaine HCl & Dextrose 5%	0.4%/5%	500 mL IV Bag	Baxter
258-0672	Lidocaine HCl w/Epi (Xylocaine® w/Epi)	1%/1:100,000	20 mL MDV	Hospira
248-0237	Lidocaine HCl w/Epi (Xylocaine® w/Epi)	2%/1:100,000	20 mL MDV	Hospira
258-2820	Magnesium Sulfate	50% (1 gm/2 mL)	2 mL SDV	American Regent
258-0220	Magnesium Sulfate	50% (10 gm/20 mL)	20 mL SDV	Hospira
258-0112	Methylene Blue	1% (10 mg/mL)	10 mL SDV	American Regent
114-8940	Metoclopramide HCl (Reglan®)	5 mg/mL	2 mL Flip Top Vial	Hospira
248-8794	Metoprolol (Lopressor®)	1 mg/mL	5 mL SD Ampule	Hospira
116-4259	Midazolam HCl (Versed®) – CIV	2 mg/2mL	10 x 2 mL iSecure Syringe	Hospira
248-0299	Midazolam HCl (Versed®) – CIV	5 mg/mL	1 mL SDV	Hospira
248-0514	Midazolam HCl (Versed®) – CIV	5 mg/mL	2 mL SDV	Hospira
102-6539	Midazolam HCl Syrup (Versed®) – CIV	2 mg/mL	118 mL Bottle	Roxane
248-0314	Nalbuphine (Nubain®)	10 mg/mL	1 mL SD Ampule	Hospira
248-9357	Naloxone HCl (Narcan®)	0.4 mg/mL	1 mL Carpuject Luer-Lock Syringe	Hospira
248-9568	Naloxone HCl (Narcan®)	0.4 mg/mL	1 mL SDV	Hospira
258-7295	Naloxone HCl (Narcan®)	0.4 mg/mL	10 mL MDV	Hospira
248-0595	Naloxone HCl (Narcan®)	1 mg/mL	2 mL Syringe (21 G x 1.5")	Internat'l Med Sys
124-1484	Neostigmine Methylsulfate (Prostigmin®)	1:1000 (1 mg/mL) 10/Bx	10 mL MDV	Fresenius
248-5055	Nitroglycerin	5 mg/mL	10 mL SDV	American Regent
277-1064	Nitroglycerin Spray (Nitrolingual®)	0.4 mg/Spray	4.9 gm (60 Dose) Bottle	Perrigo
277-1065	Nitroglycerin Spray (Nitrolingual®)	0.4 mg/Spray	12 gm (200 Dose) Bottle	Perrigo
248-0673	NitroMist® Aerosol Spray (Nitroglycerin)	0.4 mg/Spray	4.1 gm (90 Dose) Bottle	Mist Pharm
228-5292	Nitropress® (Sodium Nitroprusside)	50 mg/2 mL	2 mL SDV (I.V. Only)	Hospira
248-0674	NitroMist® Aerosol Spray (Nitroglycerin)	400 mcg./Spray	8.5 gm (230 Dose) Bottle	Mist Pharm
258-0313	Nitrostat® (Nitroglycerin)	0.4 mg (1/150 gr)	25/Bottle Sublingual Tablets	Pfizer/Upjohn
321-3802	Nitrostat® (Nitroglycerin)	0.4 mg (1/150 gr)	100/Bottle Sublingual Tablets	Pfizer/Upjohn
248-0548	Phenylephrine HCl (Neo-Synephrine®)	1% (10 mg/mL)	1 mL SDV	West-Ward
248-2309	Phenytoin Sodium (Dilantin®)	50 mg/mL	2 mL SDV	Baxter
248-0845	Phenytoin Sodium (Dilantin®)	50 mg/mL	5 mL SDV	Baxter
248-0240	Potassium Chloride	20 mEq	10 mL SDV	APP Pharma
258-7296	Procainamide HCl (Pronestyl®)	100 mg/mL	10 mL MDV	Hospira
113-2836	Procainamide HCl (Pronestyl®)	500 mg/mL	2 mL SDV	Hospira
258-4249	Promethazine HCl (Phenergan®)	25 mg/mL	1 mL SD Ampule	Baxter
248-4638	Promethazine HCl (Phenergan®)	50 mg/mL	1 mL SD Ampule	Baxter
248-0340	Propranolol HCl (Inderal®)	1 mg/mL	1 mL SDV	West-Ward
118-3633	Revonto® IV (Dantrolene Sodium)	20 mg/mL	60 mL SDV (6/Box)	US World Med
248-7957	Sodium Bicarbonate (Infant)	4.2% (5 mEq)	10 mL Abboject LifeShield Syringe	Hospira
248-8473	Sodium Bicarbonate (Infant)	8.4% (10 mEq)	10 mL Abboject LifeShield Syringe	Hospira
248-1288	Sodium Bicarbonate	8.4% (50 mEq)	50 mL Abboject LifeShield Syringe	Hospira
248-8109	Sodium Bicarbonate	8.4% (50 mEq)	50 mL SDV	Hospira
116-2590	Sodium Chloride (Bacteriostatic)	0.9%	10 mL MDV LifeShield Plastic	Hospira
258-0040	Sodium Chloride (Bacteriostatic)	0.9%	30 mL MDV Plastic	Hospira
118-0925	Sodium Chloride for Inj (Normal Saline)	0.9%	250 mL IV Bag	Hospira
258-1455	Sodium Chloride for Inj (Normal Saline)	0.9%	500 mL IV Bag	Hospira
104-6816	Sodium Chloride for Inj (Normal Saline)	0.9%	1000 mL IV Bag	Hospira
109-3041	Sodium Chloride Irrigation (Normal Saline)	0.9%	1000 mL Plastic Pour Bottle 12/Ca	Hospira
908-0011	Solu-Cortef® (Hydrocortisone Sod Succ)	100 mg	2 mL Act-O-Vial SDV	Pfizer/Upjohn
908-0013	Solu-Cortef® (Hydrocortisone Sod Succ)	250 mg	2 mL Act-O-Vial SDV	Pfizer/Upjohn
248-0255	Solu-Medrol® (Methylprednisolone Sod Succ)	40 mg/1 mL	1 mL Act-O-Vial SDV	Pfizer/Upjohn
248-0254	Solu-Medrol® (Methylprednisolone Sod Succ)	125 mg/2 mL	2 mL Act-O-Vial SDV	Pfizer/Upjohn
248-0423	Terbutaline Sulfate (Brethine®)	1 mg/mL	1 mL SDV	APP Pharma
248-0294	Tigan® (Trimethobenzamine HCl)	100 mg/mL	2 mL SDV	JHP Pharma
248-7969	Vasopressin (Pitressin®)	20U/mL	10 mL MDV	American Regent
248-0352	Verapamil (Calan®, Isoptin®)	2.5 mg/mL	2 mL SDV	Hospira
248-9359	Verapamil (Calan®, Isoptin®)	2.5 mg/mL	4 mL Ansyr Syringe	Hospira
258-0622	(Sterile) Water for Injection	Preservative-Free	10 mL Flip Top Vial Plastic	Hospira
181-9911	(Sterile) Water for Injection	Preservative-Free	50 mL Flip Top Vial Plastic	Hospira

STAT KIT® 750
emergency medical kit

- Complete set of medications
- Designed to help meet accreditation standards
- Durable, secure and mobile hard-case
- Always up to date

STAT KIT® 750 Emergency Medical Kits provide a comprehensive set of medications and devices in a mobile, durable and secure hard-case. They are organized for quick access into sections and medication trays, all clearly labeled and categorized into key areas of care. They allow the caregiver to provide BLS, ACLS and PALS and provides storage for an optional AED.

Choose the model configured for your practice:

AMBULATORY SURGERY

STAT KIT® 750-S

Includes medications & devices that meet AAAASF requirements for ambulatory surgery facilities.

Schein P/N 899-0016

RADIOLOGY & OUTPATIENT IMAGING FACILITIES

STAT KIT® 750-R

Includes medications & devices that meet the American College of Radiology Manual on Contrast Media guidelines.

Schein P/N 899-0015

For a complete list of contents, please visit statkit.com/statkit750

KMCA With Banyan's Keep-Me-Current-Automatic (KMCA) medication tracking, refill and disposal service, medication expiration dates are tracked and drugs are replaced automatically to maximize shelf-life, save money and ensure readiness.

Banyan

Life-Saving Equipment, Medications & Training Since 1970

9405 v.1 03/2015

BRAND/GENERIC COMPARISON GUIDE FOR POPULAR ITEMS

BRAND	GENERIC
Adrenalin®	Epinephrine
Ancef® Inj	Cefazolin Sod Inj
Atropen® Inj	Atropine Sulfate Inj
Benadryl®	Diphenhydramine
Bicitra®	Citric Acid/Sodium Citrate Sf
Brevibloc®	Esmolol
Bufferin® Tabs	Aspirin Buffered Tablets
Caldolor®	Ibuprofen Inj
Cardizem®	Diltiazem
Celestone Soluspan®	Betamethasone Combo
Cipro®	Ciprofloxacin
Cleocin®	Clindamycin Phosphate
Dantrium®/Revonto®	Dantrolene Sodium
Decadron® Inj	Dexamethasone
Demerol®	Meperidine
Depo-Medrol®	Methylprednisolone
Diamox Sequels®	Acetazolamide Capsules
Dilaudid®	Hydromorphone
Diprivan®	Propofol
Forane®	Isoflurane Liquid Inhalation
Garamycin®	Gentamicin
Ilotycin®	Erythromycin Ophth Ointment
Inapsine® Inj	Droperidol
Inderal®	Propranolol
Isoptin® Inj	Verapamil
Isopto Atropine® Liquid	Atropine Sulf Ophthalmic Solution
Kenalog®	Triamcinolone Acetonide
Ketalar®	Ketamine
Lanoxin®	Digoxin
Lasix®	Furosemide
Levaquin®	Levofloxacin
Levophed®	Norephinephrine
Lopressor®	Metoprolol Tartrate
Marcaine®	Bupivacaine
Motrin®/Advil®	Ibuprofen
Narcan®	Naloxone
Nexterone®	Amiodorone
Normodyne®/Trandate®	Labetalol
Nubain®	Nalbuphine
Ofirmev®	Acetaminophen Inj
Omnipen-N® Inj	Ampicillin
Phenergan®	Promethazine
Pontocaine®	Tetracaine
Quelicin®	Succinylcholine
Reglan®	Metoclopramide
Robinul®	Glycopyrrolate
Romazicon®	Flumazenil
Solu-Medrol®	Methylprednisolone Sodium Succinate
Sublimaze®	Fentanyl Citrate
Suprane®	Desflurane
Toradol®	Ketorolac
Tylenol®	Acetaminophen (Apap) Tablets
Ultane® Gas	Sevoflurane
Vancocin®	Vancomycin
Vasotec®	Enalaprilat
Versed®	Midazolam
Vicodin®	Hydrocodone W/Apap
Xylocaine®	Lidocaine
Zofran®	Ondansetron

GENERIC	BRAND
Acetaminophen (Apap) Tablets	Tylenol®
Acetaminophen Inj	Ofirmev®
Acetazolamide Capsules	Diamox Sequels®
Amiodorone	Nexterone®
Ampicillin	Omnipen-N® Inj
Aspirin Buffered Tablets	Bufferin® Tabs
Atropine Sulf Ophthalmic Solution	Isopto Atropine® Liquid®
Atropine Sulfate Inj	Atropen® Inj
Betamethasone Combo	Celestone® Soluspan®
Bupivacaine	Marcaine®
Cefazolin Sod Inj	Ancef Inj®
Ciprofloxacin	Cipro®
Citric Acid/Sodium Citrate SF	Bicitra®
Clindamycin Phosphate	Cleocin®
Dantrium/Revonto®	Dantrolene Sodium
Desflurane	Suprane®
Dexamethasone	Decadron® Inj
Digoxin	Lanoxin®
Diltiazem	Cardizem®
Diphenhydramine	Benadryl®
Droperidol	Inapsine® Inj
Enalaprilat	Vasotec®
Epinephrine	Adrenalin®
Erythromycin Ophth Ointment	Ilotycin®
Esmolol	Brevibloc®
Fentanyl Citrate	Sublimaze®
Flumazenil	Romazicon®
Furosemide	Lasix®
Gentamicin	Garamycin®
Glycopyrrolate	Robinul®
Hydrocodone W/Apap	Vicodin®
Hydromorphone	Dilaudid®
Ibuprofen	Motrin®/Advil®
Ibuprofen Inj	Caldolor®
Isoflurane Liquid Inhalation	Forane®
Ketamine	Ketalar®
Ketorolac	Toradol®
Labetalol	Normodyne®/Trandate®
Levofloxacin	Levaquin®
Lidocaine	Xylocaine®
Meperidine	Demerol®
Methylprednisolone	Depo-Medrol®
Methylprednisolone Sodium Succinate	Solu-Medrol®
Metoclopramide	Reglan®
Metoprolol Tartrate	Lopressor®
Midazolam	Versed®
Nalbuphine	Nubain®
Naloxone	Narcan®
Norephinephrine	Levophed®
Ondansetron	Zofran®
Promethazine	Phenergan®
Propofol	Diprivan®
Propranolol	Inderal®
Sevoflurane	Ultane® Gas
Succinylcholine	Quelicin®
Tetracaine	Pontocaine®
Triamcinolone Acetonide	Kenalog®
Vancomycin	Vancocin®
Verapamil	Isoptin® Inj

Celestone® Soluspan®
Injectable Suspension
6 mg/mL, 5-mL MDV
(516-0266) ..... ea

COMPARE & SAVE!



Betamethasone Sodium Phosphate and Betamethasone Acetate
Compare to Celestone® Soluspan®
6 mg/mL, 5-mL MDV
(114-8668) ..... ea

Depo-Medrol® Injectables
Methylprednisolone Acetate
40 mg/mL, 5-mL MDV
(908-9783) ..... ea
40 mg/mL, 10-mL MDV
(908-1188) ..... ea
80 mg/mL, 5-mL MDV
(908-3787) ..... ea

Depo-Medrol® Injectables
with Preservative
40 mg/mL, 1-mL SDV
(908-5362) ..... ea
40 mg/mL, 1-mL SDV
(231-1203) 25/box
80 mg/mL, 1-mL SDV
(908-7936) ..... ea
With Preservative
80 mg/mL, 1-mL SDV
(908-8623) 25/box
20 mg/mL, 5-mL MDV
(908-3069) ..... ea

Dexamethasone Sodium Phosphate Injectables
Compare to Decadron®
4 mg/mL
1-mL SDV
(122-7131) 25/pkg
5-mL MDV
(258-0122) ..... ea
(122-7115) 25/pkg
30-mL MDV
(248-0160) ..... ea
10 mg/mL
1-mL SDV
(138-6758) 25/pkg
1-mL SDV, Preservative-Free
(406-7616) 25/pkg
10-mL MDV
(112-3411) 10/pkg
10-mL MDV
(122-2910) 10/pkg

Kenalog®-40 Injectables
Triamcinolone Acetonide
40 mg/mL, 1-mL SDV
(196-8300) ..... ea
40 mg/mL, 5-mL MDV
(196-1737) ..... ea
40 mg/mL, 10-mL MDV
(196-9429) ..... ea

Solu-Medrol® Injectables
SDV, with Preservative
500 mg, 8-mL Vial
(908-6745) ..... ea
1000 mg, 16-mL Vial
(932-1096) ..... ea

Solu-Medrol® Injectables
Act-O-Vial®, Preservative-Free
40 mg, 1-mL Vial
(248-0255) ..... ea
40 mg, 1-mL Vial
(382-0014) 25/pkg
125 mg, 2-mL Vial
(248-0254) ..... ea
(382-0015) 25/pkg
500 mg, 4-mL Vial
(382-0016) ..... ea
1 gm, 8-mL Vial
(382-0017) ..... ea

Bupivacaine HCl
0.5%, 50-mL MDV
(104-6883) 25/box

Caldolor®
(Ibuprofen) Injection
For management of both surgical and nonsurgical pain.
- Caldolor is indicated in adults for:
- Management of mild to moderate pain
- Management of moderate to severe pain as an adjunct to opioid analgesics
- Reduction of fever

800 mg/8 mL, 8-mL Vial
(248-0412) 25/pkg

Hospira

Demerol HCl Carpuject- CII
50 mg../mL, 1-mL
(258-0601) 10/Box

NEW!
NSAID from
Pfizer | Hospira

Hospira

Dyloject Injection
37 mg/mL, 1-mL SDV
(258-0421) 25/box

Gebauer Company

Ethyl Chloride Spray
Topical Anesthetic Skin Refrigerant, 3½ oz Glass Bottle with Nozzle
(248-0104) ..... ea
Fine-Stream Spray
(761-1189) 4/box
(248-0103) ..... ea
Medium-Stream Spray
(761-9264) 4/box
(761-4004) 12/case
(761-8856) 12/case

Fentanyl Citrate Injectable Ampules–CII
Compare to Sublimaze®

50 mcg, 2 mL
2-mL SDV
(104-6530) 10/box

5-mL SDV
(104-6535) 10/box

Fentanyl Citrate Injectable–CII
Compare to Sublimaze®

2-mL SDV
(104-6538) 25/box

20-mL SDV
(118-9412) 5/box

Fentanyl Citrate Injectable- CII
50 mcg/mL

2-mL SDV
(118-5630) 25/box

5-mL SDV
(104-6541) 25/box

10-mL SDV
(104-6542) 25/box

20-mL SDV
(118-9435) 25/box

50-mL SDV
(118-5706) ..... ea

Kenalog®-40 Injectables
Triamcinolone Acetonide

40 mg/mL, 1-mL SDV
(196-8300) ..... ea

40 mg/mL, 5-mL MDV
(196-1737) ..... ea

40 mg/mL, 10-mL MDV
(196-9429) ..... ea

Hospira

Ketorolac Injectable
Compare to Toradol®

15 mg/mL, 1-mL SDV, IM and IV Use
(104-9907) 25/box

30 mg/mL, 1-mL SDV, Non/Returnable
(258-9639) ..... ea

30 mg/mL, 1-mL SDV, IM and IV Use
(104-9908) 25/box

60 mg/2 mL, 2-mL SDV, IM Use Only
(104-9909) 25/box

60 mg/2 mL, 2-mL SDV, Non/Returnable
(258-6520) ..... ea

Hospira

Lidocaine HCl Injection
Compare to Xylocaine®
Preservative-free. 1%, 30 mL SDV
(110-3839) 25/pkg

Lidocaine with Epinephrine Injectable
Compare to Xylocaine® with Epinephrine

1%, 30-mL MDV
(248-3556) ..... ea
(104-6822) 25/box

Hospira

Lidocaine HCl Injectable
Compare to Xylocaine®
50-mL MDV

1%
(248-0644) ..... ea
(104-6817) 25/box

2%
(248-3041) ..... ea
(104-9843) 25/box

Hospira

Lidocaine 1% with Epinephrine 1:100 Injectable
Compare to Xylocaine® with Epinephrine

50-mL MDV
1%, 50-mL MDV
(248-7453) ..... ea
(104-7099) 25/box

Hospira

Lidocaine HCl with Epinephrine Injectable*
Compare to Xylocaine® with Epinephrine

1%, 50-mL MDV
(248-7453) ..... ea

2%, 30-mL MDV
(248-5394) ..... ea

2%, 50-mL MDV
(248-1961) ..... ea

**Call for availability.*

Lidocaine 2% Jelly Urojet

5 mL
(118-2153) 25/box

10 mL
(118-2154) 25/box

Hospira

Marcaine Injectable

0.25%, 50-mL MDV
(258-7402) ..... ea

0.5%, 50-mL MDV
(631-2615) ..... ea

Medication Delivery is Vital

LET'S do it safely and efficiently

Morphine Sulfate

Injection, USP CII

Now Available in iSecure™

Efficiently delivering medication while supporting patient and caregiver safety is at the core of our iSecu technology. Choose the prefilled syringe designed to improve workflow efficiency and safety, while never losing sight of what's ultimately most important—your patients.

Product Description	Qty/Pack	NDC No.	Catalog No.
Hydromorphone Hydrochloride Inj., USP (0.5 mg/0.5 mL) CII, iSecure	10	0409-1283-05	121-0754
Hydromorphone Hydrochloride Inj., USP (1 mg/mL) CII, iSecure	10	0409-1283-10	121-0755
Hydromorphone Hydrochloride Inj., USP (2 mg/mL) CII, iSecure	10	0409-1312-10	121-0827
Ketorolac Tromethamine Inj., USP (30 mg/mL), iSecure	10	0409-2287-23	121-0751
Midazolam Hydrochloride Inj., USP (2 mg/2 mL) CIV, iSecure	10	0409-2306-12	116-4259
Morphine Sulfate Inj., USP (2 mg/mL) CII, iSecure	10	0409-1890-11	121-2158
Morphine Sulfate Inj., USP (4 mg/mL) CII, iSecure	10	0409-1891-11	121-2157
Ondansetron Inj., USP (4 mg/2 mL), iSecure	10	0409-1120-12	118-1696

Multiple levels of tamper evidence help maintain product integrity and prevent drug diversion

Prefilled, single-dosing helps to ensure accuracy of drug delivery and reduce medication errors

Customer-inspired intuitive design that fits comfortably in the palm of your hand

No additional supplies saves time and lowers costs

For more information, contact your sales representative at 1-877-9HOSPIRA (946-7747) or visit hospira.com.

Hospira, Inc., 275 North Field Drive, Lake Forest, IL 60045
P14-0200-Mar., 14

iSecure™ SYRINGE Hospira

WE'RE INNOVATING TODAY...

For Susan K's Carpal Tunnel Relapse

For Mavis T's Cataract Extraction

For Karl O's Gastroscopy

For Kate H's Cardioversion

...WITH OUR 10 mL VIAL

Designed for added convenience and flexibility.

We've introduced a 10 mL DIPRIVAN® (Propofol) Injectable Emulsion, USP vial for single-patient infusion, available exclusively from Fresenius Kabi. It's just one of the ways we innovate to stay in the lead.

For prescribing information, visit
www.diprivan10ml.com

Safety Information

DIPRIVAN Injectable Emulsion is contraindicated in patients with a known hypersensitivity to DIPRIVAN Injectable Emulsion or any of its components, and also in patients with allergies to eggs, egg products, soybeans or soy products. Use of DIPRIVAN Injectable Emulsion has been associated with both fatal and life-threatening anaphylactic and anaphylactoid reactions, as well as Propofol Infusion Syndrome. For general anesthesia or MAC sedation, DIPRIVAN Injectable Emulsion should be administered only by persons trained in the administration of general anesthesia and not involved in the conduct of the surgical/diagnostic procedure. For sedation of intubated, mechanically ventilated patients in the ICU, DIPRIVAN Injectable Emulsion should be administered only by persons skilled in the management of critically ill patients and trained in cardiovascular resuscitation and airway management. Sedated patients should be continuously monitored. Strict aseptic technique must always be maintained during handling. DIPRIVAN Injectable Emulsion is a single access parenteral product. Failure to use aseptic technique has been associated with microbial contamination of the product, including fever, infection/sepsis, other life-threatening illness and/or death. There have been reports, in the literature and other public sources, of the transmission of bloodborne pathogens (such as Hepatitis B, Hepatitis C, and HIV) from unsafe injection practices, and use of propofol vials intended for single use on multiple persons. DIPRIVAN Injectable Emulsion vials are never to be accessed more than once or used on more than one person.

FRESENIUS KABI
caring for life

DIPRIVAN® (Propofol) INJECTABLE EMULSION, USP

0998-DIP-05-11/15

PAIN MANAGEMENT

Hospira

Marcaine® with Epinephrine Injectable
0.25%, 50-mL MDV
(631-2847) ..... ea

0.5%, 50-mL MDV
(631-2615) ..... ea

0.5%, 50-mL MDV
(258-9815) ..... ea

0.25%, 30-mL SDV
(258-4709) 10/box

Hospira

Naloxone HCl Injectable
0.4 mg/mL
1-mL SDV
(104-6876) 10/box

10-mL MDV
(258-7295) ..... ea

1-mL Carpuject Syringe
(104-9657) 10/box

APP

Naropin Injectable
A long-acting amide-type anesthetic indicated for the production of local or regional anesthesia for surgery and for acute pain management.
5 mg/mL, 30-mL SDV
(150-0133) 25/pkg

COMPARE & SAVE!

Hospira

Ropivacaine HCl Injection
Compare to Naropin®
2 mg/mL, 10-mL SDV
(122-4991) 10/box

2 mg/mL, 20-mL SDV
(122-4990) 10/box

5 mg/mL, 30-mL SDV
(122-4989) 10/box

7.5 mg/mL, 20-mL SDV
(122-4983) 10/box

10 mg/mL, 10-mL SDV
(122-4986) 10/box

10 mg/mL, 20-mL SDV
(122-4984) 10/box

Mallinckrodt Pharmaceuticals

OFIRMEV™ (Acetaminophen) Injection
Indicated for the:
- Management of mild to moderate pain
- Management of moderate to severe pain with adjunctive opioid analgesics
- Reduction of fever

10 mg/mL, 100-mL Vial
(228-3370) 24/case

Gebauer Company

Pain Ease® Mist Spray
Topical Anesthetic Skin Refrigerant, 3½-oz Cans
For topical application to skin, intact mucous membranes (oral cavity, nasal passageways, and lips) and minor open wounds.
- Works in seconds; no waiting as with anesthetic creams
- Easy to use: swab area with antiseptic, spray for a few seconds, and perform procedure
- Temporary numbing lasts up to 1 minute; reapply as needed

3.5-oz Mist Spray, Medium
(761-0465) ..... ea

Stream Spray, Medium
(761-3279) ..... ea

1-oz Single-Patient-Use Stream Spray, Medium
(761-0023) NEW! 24/box
Can be used in facilities that restrict use of flammable components.

APP

Xylocaine Plain
1%, 5-mL SDV, MPF
(150-0069) 25/box

1%, 10-mL Polypropylene Ampule
(150-6188) ..... 5 amp/pkg

1%, 30-mL SDV, MPF
(150-0072) 25/pkg

1%, 50-mL MDV
(248-0409) ..... ea

1%, 50-mL MDV
(150-0119) 25/pkg

2%, 5-mL SDV, MPF
(150-0101) 25/pkg

APP

Xylocaine® with Epinephrine Injectable
1%, 50-mL MDV
(248-0350) ..... ea

(150-0073) 25/pkg

2%, 50-mL MDV
(248-0414) ..... ea

(150-0097) 25/pkg

Diprivan Injectable
10 mg/mL, 10-mL SDV
(150-0143) 10/box

10 mg/mL, 20-mL SDV
(150-0131) 10/box

10 mg/mL, 50-mL SDV
(110-7244) 20/box

Hospira

Propofol Injectable*
10 mg/mL
Compare to Diprivan®
20-mL SDV
(248-6832) 5/box
**Benzyl alcohol as preservative.*
Call for Availability

Hospira

Propofol Injectable*
10 mg/mL, 50-mL SDV
(110-1262) 20/box

Without Sulfate
100-mL SDV, 10 mg/mL
(110-7216) 10/pkg
**Benzyl alcohol as preservative.*
Call for availability.

Ultane® Anesthesia Liquid Inhalation 100%
250-mL Bottle
(403-5745) ..... ea

COMPARE & SAVE!

Sevoflurane Liquid Inhalation 100%
Compare to Ultane®
250 mL/btl
(116-9356) ..... ea

Suprane® Liquid for Inhalation (Desflurane)
Nonreturnable
99%, 240-mL Bottle
(248-0572) ..... ea

(119-8513) 6/case

HENRY SCHEIN®
MEDICAL

Is your ASC **still** using the triplicate paper DEA Form-222 for ordering Schedule II controlled substances?

You can make your ASC more efficient by enrolling in

Henry Schein's Electronic Schedule II Drug Ordering (e222) System!

Steps to Enrollment:

1. Enroll with the DEA for a CSOS Certificate*
2. Enroll into Henry Schein's e222
3. Place your e222 order

****Already have a CSOS Certificate? Enrollment will be even faster!***

With the use of a CSOS (Controlled Substance Ordering System) certificate issued to you by the DEA, you can enroll in e222 and benefit from:

- **Faster Delivery** by immediate receipt of e222 form
- **Increased Order Accuracy**
- **Decreased Paperwork**
- **Ordering Freedom**, enabling you to order any time from any computer with access to your stored CSOS digital certificate

Enroll Now! Visit www.henryschein.com/e222 for complete enrollment instructions.
You may also ask your Sales Consultant or call 800-532-0766 for more details.

The First and Only FDA Approved 2 gram Cefazolin.

The 2 gram dose of Cefazolin for Injection USP is readily available in the DUPLEX® Drug Delivery System, only from B. Braun Medical.

- 19-month expiration rating
- Fits in automated dispensing systems
- Easy bedside activation - no thawing or mixing vials
- Room-temperature storage

Cefazolin for Injection USP and Dextrose Injection USP

Dosage	NDC	Henry Schein Reorder #
2g/50ml	0264-3105-11	118-2036
1g/50ml	0264-3103-11	109-3074

Ready to use wherever, whenever you need Cefazolin 2g quickly.

B|BRAUN SHARING EXPERTISE

www.bbraunusa.com

 12-3130_HS_3/12_KE

SILVRSTAT® Antibacterial Wound Dressing Gel

STOP MRSA NOW with SilvrSTAT®!

- **SilvrSTAT* is the only multivalent silver FDA-indicated to inhibit & kill MRSA!**
- MRSA is one of the most troubling health care concerns causing over 94,000 hospitalization and 18,000 deaths per year
- SilvrSTAT is a NEW type of silver that immediately and continuously kills harmful bacteria–A MORE POWERFUL MANAGEMENT OPTION!

Consider SilvrSTAT® if you are using the following products:

- Silvadene® (silver sulfadiazene)
- Silvasorb®
- SilverMed® and Amerigel®
- Gentell's Silver Hydrogel Ag®
- Elta's SilverGel™ Advanced Silver
- DermaSyn®/Ag Antimicrobial Silver
- any Hydrogel
- Bactroban® (mupirocin)

Protect Your Patients Against Community Acquired Infections

Reimbursed as a hydrogel using HCPCS code A6248†

SilvrSTAT® (Rx) Antibacterial Wound Dressing Gel
(685-0183).....1 oz.

(685-0184).....3 oz.

BEST VALUE
Save 24% vs. the 1 oz. size!

*Caution: Federal law restricts the sale of this device by, or on the order of, a licensed health care practitioner.
†For informational purposes only. Source: PresidiumLabs, LLC. Customer is responsible for verification of billing/coding in accordance with applicable specific circumstances.

Item Code	Description	Size	Manufacturer
PRE-OP ROOM			
(118-5678)	Ampicillin Inj SDV, 1 Gm, 10 mL	10/Box	AuroMedics Pharma
(118-5680)	Ampicillin Inj SDV, 2 Gm, 10 mL	10/Box	AuroMedics Pharma
(248-0486)	Atropine Sulfate Inj MDV, 0.4 mg/mL, 20 mL	1/Vial	West-Ward Pharma
(118-1325)	Cefazolin Sod Inj SDV, 500 mg, 10 mL	1/Vial	Sandoz, Inc.
(248-9422)	Cefazolin Sod Inj SDV, 1 Gm, 15 mL	1/Vial	Hospira Worldwide, Inc.
(109-3074)	Cefazolin Sod and Dextrose Inj 1 Gm, 50 mL Bag	24/Case	B Braun
(118-2036)	Cefazolin Sod and Dextrose Inj 2 Gm, 50 mL Bag	24/Case	B Braun
(104-8957)	Citric Acid/Sodium Citrate SF (Bicitra©) 16 oz/Btl.	Btl.	Pharmaceutical Associates
(108-5614)	Clindamycin Phosphate Inj SDV, 150 mg/mL, 6 mL	25/Box	Hospira Worldwide, Inc.
(104-9944)	Gentamicin Sulfate Inj SDV, 40 mg/mL, 2 mL	25/Box	Hospira Worldwide, Inc.
(258-5707)	Vancomycin HCl Inj SDV, 500 mg	1/Vial	Hospira Worldwide, Inc.
(104-6847)	Vancomycin HCl Inj SDV, 1 Gm	10/Box	Hospira Worldwide, Inc.
ANESTHESIA ROOM			
(472-4712)	Acetaminophen (APAP) Suppos, Pediatric, 120 mg	12/Box	Perrigo Pharmaceuticals
(277-0107)	Acetaminophen (APAP) Suppos, 325 mg	12/Box	G & W Labs Inc.
(116-1818)	Albuterol Inhalation Solution, 3 mL, 0.083%	25/Ctr	Nephron Pharmaceuticals Corp
(248-0458)	Nexterone© IV Bag Premixed, 360 mg/200 mL	10/Case	Baxter Anesthetic & Crit Care
(118-7740)	Atropine Sulfate Inj Syr, Pres Free, 0.1 mg/mL	10/Box	Int'l Medication Systems
(258-0069)	Atropine Sulfate Inj SDV, 0.4 mg/mL, 1 mL	1/Vial	American Regent
(248-0475)	Atropine Sulfate Inj SDV, 0.4 mg/mL, 20 mL	10/Box	West-Ward Pharmaceutical
(228-3183)	Atrovent© HFA Aerosol Inhaler, 17 mcg/Dose, 12.9 Gm	Ea.	Boehringer Ingelheim
(248-8933)	Brevibloc© Inj SDV 10 mg/mL, 10 mL	25/Box	Baxter Anesthetic & Crit Care
(110-7661)	Bupivacaine HCl Inj SDV, 0.5%, 10 mL	25/Box	Hospira Worldwide, Inc.
(248-7214)	Calcium Chloride Ansyr Syr, 10%, 10 mL	10/Box	Hospira Worldwide, Inc.
(635-2470)	Cetacaine© Topical Spray, 56 gm/Btl.	Btl.	Cetylite Industries Inc.
(122-7131)	Dexamethasone Sod Phos Inj MDV, 4 mg/mL, 1 mL	25/Box	Mylan
(258-0122)	Dexamethasone Sod Phos Inj MDV, 4 mg/mL, 5 mL	1/Vial	APP Pharmaceutical
(248-1659)	Digoxin Inj SD Ampule, 0.25 mg/mL, 2 mL	1/Ea.	Baxter Anesthetic & Crit Care
(124-3563)	Diltiazem HCl Inj SDV, 5 mg/mL, 5 mL	10/Box	West-Ward Pharmaceutical
(258-5924)	Diphenhydramine HCl Inj SDV, 50 mg/mL, 1 mL	1/Vial	Baxter Anesthetic & Crit Care
(277-0037)	Diphenhydramine HCl Inj SDV, 50 mg/mL, 1 mL	25/Box	West-Ward
(150-0143)	Diprivan Inj SDV, 10 mg/mL, 10 mL	10/Box	APP Pharmaceutical
(150-0131)	Diprivan Inj SDV, 10 mg/mL, 20 mL	10/Box	APP Pharmaceutical
(109-3092)	Droperidol Inj SDV, 2.5 mg/mL, 2 mL	25/Box	American Regent Inc.
(111-8364)	Enlon© Inj MDV, 10 mg/mL, 15 mL	1/Vial	Bioniche Pharma
(107-7160)	Enalaprilat Inj SDV, 1.25 mg/mL, 2 mL	1/Vial	Hospira Worldwide, Inc.
(248-8175)	Epinephrine Inj ABJ LFS Syr, 1:10,000, 10 mL	Ea.	Hospira Worldwide, Inc.
(258-9483)	Epinephrine Inj SD Ampule, 1:1000, 1 mg/mL	5/Pk	Hospira Worldwide, Inc.
(345-1926)	Epipen® (Adult) 0.3 mg, Prefilled Syringes	2/Pk	Dey
(345-3230)	Epipen® (Junior) 0.15 mg, Prefilled Syringes	2/Pk	Dey
(277-1282)	Epinephrine Auto-injector 0.3 mg (Adult), Prefilled Syringes	2/Pk	Amedra
(277-1281)	Epinephrine Auto-injector 0.15 mg (Junior), Prefilled Syringes	2/Pk	Amedra
(122-5494)	Esmolol HCl Pres Free Inj SDV, 10 mg/mL	10/Box	Mylan
(104-6530)	Fentanyl Citrate Inj SD Ampule, 50 mcg./mL, 2 mL – CII	10/Box	Hospira Worldwide, Inc.
(104-6538)	Fentanyl Citrate Inj SDV, 50 mcg/mL, 2 mL – CII	25/Box	Hospira Worldwide, Inc.
(104-6535)	Fentanyl Citrate Inj SD Ampule, 50 mcg/mL, 5 mL – CII	10/Box	Hospira Worldwide, Inc.
(248-0626)	Flumazenil Inj MDV, 0.1 mg/mL, 5 mL	1/Vial	West-Ward
(121-4498)	Flumazenil Inj MDV, 0.1 mg/mL, 10 mL	1/Vial	West-Ward
(181-3332)	Furosemide Inj SDV, 10 mg/mL, 2 mL	1/Vial	Hospira Worldwide, Inc.
(160-6703)	Glycopyrrolate Inj SDV, 0.2 mg/mL, 1 mL	25/PK	American Regent Inc.
(120-7036)	Glycopyrrolate Inj SDV, 0.2 mg/mL, 2 mL	25/Box	West-Ward Pharmaceutical
(248-0407)	Hydralazine Inj SDV, 20 mg/mL, 1 mL	1/Vial	APP Pharmaceutical
(104-9895)	Hydralazine Inj SDV, 20 mg/mL, 1 mL	25/Box	APP Pharmaceutical
(104-6874)	Ketamine HCl Inj MDV, 50 mg/mL, 10 mL – CIII	10/Box	Hospira Worldwide, Inc.
(104-4102)	Ketamine HCl Inj MDV, 100 mg/mL, 5 mL – CIII	10/Box	Hospira Worldwide, Inc.
(258-9639)	Ketorolac Tromethamine Inj SDV, 30 mg/mL, 1 mL	1/Vial	Hospira Worldwide, Inc.
(840-8589)	Labetalol HCl Inj MDV, 5 mg/mL, 20 mL	1/Vial	Hospira Worldwide, Inc.
(258-7008)	Lidocaine HCl Inj MDV, 1%, 20 mL	1/Vial	Hospira Worldwide, Inc.
(248-0235)	Lidocaine HCl Inj SDV, Pres Free, 2%, 5 mL	1/Vial	Hospira Worldwide, Inc.

Item Code	Description	Size	Manufacturer
ANESTHESIA ROOM, cont'd.			
(323-2446)	Lidocaine HCl Inj SDV, Pres Free, 2%, 5 mL	25/Box	APP Pharmaceuticals
(108-7250)	Lidocaine HCl Inj Ampule, 4%, 5 mL	25/Box	Hospira Worldwide, Inc.
(201-3928)	Lidocaine Topical Ointment, 5%, 1.25 oz/Tube	1/Tube	E Fougera & Company
(114-8940)	Metoclopramide Inj SDV, Pres Free, 5 mg/mL, 2 mL	1/Vial	Hospira Worldwide, Inc.
(114-6842)	Metoclopramide Inj SDV, Pres Free, 5 mg/mL, 2 mL	25/Box	Hospira Worldwide, Inc.
(248-8794)	Metoprolol Tartrate Inj Ampule, 1 mg/mL, 5 mL	Ea.	Hospira Worldwide, Inc.
(258-0101)	Midazolam HCl Inj SDV, 1 mg/mL, 2 mL – CIV	25/Box	Hospira Worldwide, Inc.
(116-4259)	Midazolam HCl Inj Isecure Syringe, 1 mg/mL, 2 mL – CIV	10/Box	Hospira Worldwide, Inc.
(277-0271)	Midazolam HCl Syrup, 2 mg/mL – CIV	118 mL/Btl.	Roxane
(104-6858)	Nalbuphine Inj Ampule, 10 mg/mL, 1 mL	10/Box	Hospira Worldwide, Inc.
(248-9568)	Naloxone HCl Inj SDV, 0.4 mg/mL, 1 mL	1/Vial	Hospira Worldwide, Inc.
(104-6876)	Naloxone HCl Inj SDV, 0.4 mg/mL, 1 mL	10/Box	Hospira Worldwide, Inc.
(150-0133)	Naropin© Inj SDV, 5 mg/mL, 30 mL	1/Vial	Fresenius
(123-8768)	Nasal Spray – Oxymetazoline (Afrin©), 0.05%, 0.5 oz/Btl.	1/Btl.	Major Pharmaceuticals
(124-5698)	Neostigmine Methylsulfate Inj, 0.5 mg/mL, 10 mL,	10/Box	Eclat
(248-0455)	Nexterone© IV Bag Premixed, 150 mg/100 mL *Nexterone© (Amiodarone HCl) Premixed Injection is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy.*	12/Case	Baxter Anesthetic & Crit Care
(277-1064)	Nitroglycerin Spray, 0.4 mg/Spray	60 Dose/Btl.	Clay
(277-1065)	Nitroglycerin Spray, 0.4 mg/Spray	200 Dose/Btl.	Clay
(248-0673)	NitroMist© Aerosol Spray, 400 mcg/Spray	90 Dose/Btl.	Mist Pharmaceuticals
(258-0313)	Nitrostat© Sublingual Tablets, 0.4 mg (1/150 Gr)	25/Btl.	Pfizer
(277-0487)	Ondansetron Inj SDV, 2 mg/mL, 2 mL	10/Box	Heritage Pharmaceuticals
(123-4826)	Ophthalmic Oint, Lacri-Lube SOP©, 7 gm Tube	Tube	Allergan Pharm, Inc.
(248-0548)	Phenylephrine Inj SDV, 10 mg/mL, 1 mL	1/Vial	West-Ward Pharmaceuticals
(119-5724)	Phenylephrine Inj SDV, 10 mg/mL, 1 mL	25/Box	West-Ward Pharmaceuticals
(258-4249)	Promethazine HCl Inj Ampule, 25 mg/mL, 1 mL	Ea.	Baxter Anesthetic & Crit Care
(102-7248)	Promethazine HCl Inj SDV, 25 mg/mL, 1 mL	25/Box	Baxter Anesthetic & Crit Care
(122-9854)	Promethazine HCl Suppositories, 25 mg	12/Box	Watson Pharmaceuticals
(248-6832)	Propofol Inj SDV, 10 mg/mL, 20 mL (w/Benzyl Alcohol)	5/Box	Hospira Worldwide, Inc.
(110-1262)	Propofol Inj SDV, 10 mg/mL, 50 mL (w/Benzyl Alcohol)	20/Box	Hospira Worldwide, Inc.
(248-0340)	Propranolol HCl Inj SDV, 1 mg/mL, 1 mL	1/Vial	West-Ward Pharmaceuticals
(116-2121)	Racepinephrine (S2) Inhalation Sol, 2.25%, 0.5 mL	30/Box	Nephron Pharm Corp
(840-8619)	Rocuronium Bromide Inj MDV, 10 mg/mL, 5 mL	10/Pk	Pharma Hospira
(104-9687)	Sevoflurane Inhalation Liquid, 250 mL Btl.	6/Box	Baxter Anesthetic & Crit Care
(248-8109)	Sodium Bicarbonate Inj SDV, 8.4% (8.4% mEq), 50 mL	1/Vial	Hospira Worldwide, Inc.
(248-4457)	Sodium Chloride Inj SDV, Pres Free, 0.9%, 10 mL	1/Vial	Hospira Worldwide, Inc.
(104-9943)	Sodium Chloride Inj SDV, Pres Free, 0.9%, 10 mL	25/Box	Hospira Worldwide, Inc.
(123-9943)	Sodium Citrate Citric Acid Chemical, 15 mL, 100 Btl.	100/Case	Pharmaceutical Associates
(248-0254)	Solu-Medrol© Inj Act-O-Vial, Pres Free, 125 mg, 2 mL	1/Vial	Pfizer
(104-6965)	Succinylcholine Chl Inj MDV, 20 mg/mL, 10 mL	25/Box	Hospira Worldwide, Inc.
(228-2905)	Transderm-Scop© Transdermal Patches, 1.5 mg	4/Box	Novartis
(424-0046)	Ultiva© IV Inj Vial, 1 mg/3 mL – CII	10/Box	Bioniche Pharma
(424-0047)	Ultiva© IV Inj Vial, 2 mg/5 mL – CII	10/Box	Bioniche Pharma
(228-3341)	Ventolin© HFA Inhaler, 0.09%/Spray, 8 gm	Ea.	GSK
(228-3204)	Ventolin© HFA Inhaler, 0.09%/Spray, 18 gm	Ea.	GSK
(104-7052)	Verapamil Inj. 2.5 mg/mL, 2 mL Vials	5/Box	Hospira Worldwide, Inc.
(258-0622)	(Sterile) Water for Inj, Pres Free, Vial, 10 mL	1/Vial	Hospira Worldwide, Inc.
(104-7823)	(Sterile) Water for Inj, Pres Free, Vial, 10 mL	25/Box	Hospira Worldwide, Inc.
OPERATING ROOM			
(123-9450)	Atropine Sulfate Ophth Sol, 1%	15 mL/Btl.	Akorn
(121-8942)	Bacitracin Ophthalmic Oint, 500U/gm, 1/8 oz	1/Tube	Clay Pharmaceuticals
(908-8136)	Bacitracin Pwd For Inj Vial, 50,000U	1/Vial	Pfizer
(108-9063)	Bupivacaine HCl w/Epi Inj SDV, 0.25%/1:200M, 10 mL	10/Box	Hospira Worldwide, Inc.
(110-0834)	Bupivacaine HCl Inj SDV, 0.75%, 10 mL	25/Box	Hospira Worldwide, Inc.
(115-6265)	Cyclogyl© Ophthalmic Sol, 2% 5 mL/Btl.	1/Btl.	Alcon Laboratories Inc.
(115-7589)	Dantrolene sodium/DANTRIUM© Inj SDV, 20 mg/mL, 60 mL	6/Box	JHP Pharmaceuticals
(118-3633)	Dantrolene sodium/REVONTO© Inj SDV, 20 mg/mL, 60 mL	6/Box	US World Meds
(908-5362)	Depo-Medrol 40 mg/mL 1 mL SDV w/Preservatives	1/Vial	Pfizer

Item Code	Description	Size	Manufacturer
OPERATING ROOM, cont'd.			
(258-9483)	Epinephrine Inj Ampule, 1:1000, 1 mg/mL	5/Pk	Hospira Worldwide, Inc.
(112-7191)	Erythromycin Ophth Ointment, 0.5%, 3.5 gm Tube	1/Tube	Henry Schein, Inc.
(104-3735)	Ful-Glo© Ophthalmic Strips, 1 mg	100/Box	Akorn,Inc.
(289-0000)	Exparel 1.3%	10/Box	Pacira Pharmaceuticals
(375-8394)	Heparin Sodium (Porcine) Inj MDV, 1,000u/mL, 1 mL	25/Box	APP Pharmaceuticals
(258-0105)	Heparin Sodium (Porcine) Inj MDV, 1,000u/mL, 10 mL	25/Box	Hospira Worldwide, Inc.
(118-2098)	Isoflurane Liquid Inhalation, 99.9%	100 mL/Btl.	Piramal Critical Care
(118-2097)	Isoflurane Liquid Inhalation, 99.9%	250 mL/Btl.	Piramal Critical Care
(248-7963)	Levophed© (Norepinephrine Bitart) Inj SD Amp, 1 mg/mL, 4 mL	1/Ea.	Hospira Worldwide, Inc.
(258-7008)	Lidocaine HCl Inj MDV, 1%, 20 mL	1/Vial	Hospira Worldwide, Inc.
(258-0603)	Lidocaine HCl Inj MDV, 2%, 20 mL	1/Vial	Hospira Worldwide, Inc.
(248-0237)	Lidocaine HCl w/EPI Inj MDV, 1%/100,000, 20 mL	1/Vial	Hospira Worldwide, Inc.
(248-7453)	Lidocaine HCl w/EPI Inj MDV, 1%/100,000, 50 mL	1/Vial	Hospira Worldwide, Inc.
(277-0528)	Lidocaine HCl Topical Sol 4% 50 mL/Btl.	1/Btl.	Roxane
(248-0493)	Lidocaine Inj Jelly Urojet, 2%, 10 mL	1/Ea.	Int'l Medication Systems
(277-0718)	Lydocaine© Jelly, 2%, 30 mL Tube	1/Tube	Akorn, Inc.
(258-2245)	Marcaine© Inj SDV, 0.25%, 10 mL	1/Vial	Hospira Worldwide, Inc.
(258-1993)	Marcaine© Inj SDV, 0.5%, 10 mL	1/Vial	Hospira Worldwide, Inc.
(111-8716)	Mineral Oil Heavy, 16 oz/Btl.	1/Btl.	Cumberland Swan
(123-8768)	Nasal Spray – Oxymetazoline (Afrin©), 0.05%	0.5 oz/Btl.	Major Pharmaceuticals
(111-8933)	Pilocarpine Ophthalmic Sol, 1%	15 mL/Btl.	Falcon Pharmaceuticals
(117-3465)	Pilocarpine Ophthalmic Sol, 4%	15 mL/Btl.	Sandoz
(555-3169)	Prep Solution, Hibiclens© Antimicrobial, 4%	8 oz/Btl.	Molnlycke Healthcare
(116-9356)	Sevoflurane Liquid Inhalation, 100%	250 mL/Btl.	Piramal Critical Care
(277-0017)	Silver Nitrate Applicators, Plastic stick 6"	100/Vial	Tech-Med Services
(277-0391)	Silver Sulfadiazine Cream (SSD), 1%	85 gm/Tube	Ascend Laboratories
(248-0572)	Suprane© Liquid Inhalation, 99%	240 mL/Btl.	Baxter Anesthetic & Crit Care
(119-8513)	Suprane© Liquid Inhalation, 240 mL, 99%	6/Case	Baxter Anesthetic & Crit Care
(115-6385)	Tetracaine HCl Inj Ampule, 1%, 2 mL	25/Pk	Akorn, Inc.
(110-8016)	Thrombin© JMI Inj Vial, 5,000U, 5 mL	1/Vial	King Pharmaceuticals Inc.
(112-7192)	Tropicamide Ophthalmic Sol, 1%, 15 mL/Btl.	1/Btl.	Henry Schein, Inc.
(403-5745)	Ultane© Liquid Inhalation, 100%	250 mL/Btl.	Abbott Pharmaceutical
(150-0069)	Xylocaine© MPF Inj SDV, 1%, 5 mL	25/Box	APP Pharmaceuticals
(150-6188)	Xylocaine© MPF Inj Vial, 1%, 10 mL	5/Pk	APP Pharmaceuticals
(150-0101)	Xylocaine© Inj SDV, Pres Free, 2%, 5 mL	25/Box	APP Pharmaceuticals
RECOVERY ROOM			
(115-8484)	Acetaminophen (APAP) Oral Elixir, 160 mg/5 mL, Cherry	16 oz/Btl.	Geri-Care Pharmaceuticals
(228-3370)	Ofirmev© Inj IV Vial, 10 mg/mL, 100 mL (Acetaminophen Inj)	24/Case	Cadence Pharmaceuticals
(277-0416)	Acetazolamide Capsules, U/D Blist Pk, 500 mg	30/Box	American Health Products
(692-0432)	Ammonia Inhalant Ampules	10/Box	Pacc-Kit Safety Equipment
(277-0534)	APAP w/Codeine Tablets, 60 mg – CIII	500/Btl.	Qualitest Pharmaceuticals
(104-8935)	APAP w/Codeine Oral Elixir, 12 mg/5 mL – CV	120 mL/Btl.	Pharmaceutical Associates
(120-0794)	APAP Extra Strength Tablets, 500 mg	100/Btl.	New World
(119-8132)	Aspirin 325 mg Tablets Enteric Coated	100/Btl.	Time-Cap Labs
(123-9450)	Atropine Sulf Ophthalmic Sol, 1%	15 mL/Btl.	Falcon Pharmaceuticals
(277-0738)	Ciprofloxacin HCl Tablets, 500 mg	100/Btl.	Clay
(123-7441)	Cocaine Topical Sol, 4% – CII	4 mL/Btl.	Lannett Co, Inc.
(248-0297)	Dextrose ABJ LFS Inj Syringe, 50%, 50 mL	1/Ea.	Hospira Worldwide, Inc.
(277-0520)	Hydrocodone w/APAP Tablets, 5 mg/325 mg – CIII	100/Btl.	Amneal
(104-6409)	Hydromophone Inj Carpuject, 1 mg/mL – CII	10/Box	Hospira Worldwide, Inc.
(118-6598)	Ibuprofen Tablets, 200 mg	100/Btl.	New World Imports
(248-0412)	Caldolor© Inj IV, 800 mg (Ibuprofen Inj)	25/Pk	Cumberland Pharmaceuticals
(118-1985)	Meperidine HCl Inj SDV, 50 mg/mL, 1 mL – CII	25/Box	West-Ward Pharmaceuticals
(629-0004)	Meperidine HCl Inj SDV, 100 mg/mL, 1 mL – CII	25/Box	West-Ward Pharmaceuticals
(277-0271)	Midazolam Oral Syrup, 2 mg/mL – CIV	118 mL/Btl.	Roxane Pharmaceuticals
(118-2054)	Morphine Sulf Inj SDV, 5 mg – CII	25/Box	West-Ward Pharmaceuticals
(118-2053)	Morphine Sulf Inj SDV, 10 mg – CII	25/Box	West-Ward Pharmaceuticals
(191-0000)	Nitro-Bid© Oint, 2%, Foilpacs, 1 gm	48/Box	Savage Labs
(124-0851)	Phenazopyradine Tablets, 100 mg	100/Btl.	ECI Pharmaceuticals

HENRY SCHEIN® BRAND PRODUCTS | BRAND PROMISE

Introducing

HENRY SCHEIN OPHTHALMIC OINTMENTS & SOLUTIONS

112-7195 ***Coming Soon!***
BACITRACIN ZINC/NEO/POLY/HC OPHTH OINTMENT
3.5gm/Tube
Compare to CORTISPORIN® OPHTH OINTMENT

112-7187
CIPROFLOXACIN HCL OPHTH SOLUTION
0.3% 5mL/Bottle
Compare to CILOXAN® SOLUTION

112-7191 ***Coming Soon!***
ERYTHROMYCIN OPHTH OINTMENT
0.5% 3.5gm/Tube
Compare to ILOTYCIN® OPHTH OINTMENT

112-7189
OFLOXACIN OPHTHALMIC SOLUTION
0.3% 10mL/Bottle
Compare to OCUFLOX® SOLUTION

112-7194 ***Coming Soon!***
TRIPLE ANTIBIOTIC OPHTH OINTMENT
3.5gm/Tube
Compare to NEOSPORIN® OPHTH OINTMENT

112-7196
TOBRAMYCIN OPHTH SOLUTION
0.3% 5mL/Bottle
Compare to TOBREX® SOLUTION

112-7199
PROPARACAINE HCL OPHTH SOLUTION
0.5% 15mL/Bottle
Compare to OPHTHAINE® SOLUTION

112-7192
TROPICAMIDE OPHTH SOLUTION
1% 15mL/Bottle
Compare to MYDRIACYL® SOLUTION

Rely On Us for Quality, Selection and Performance. Rely on Us

Item #	Description	Size	Manufacturer
(119-7493)	Acetazolamide Sodium Inj Vial 500mg	10mL/Vl	Sagent Pharmaceuticals
(245-0058)	Akten® (lidocaine) Ophthalmic Gel 3.5%	1mL/Bt	Akorn,Inc.
(101-0853)	Artificail Tears (Akwa®) Ophthalmic Oint 3.5gm	1/Tb	Akorn,Inc.
(123-8582)	Atropine Sulfate Ophthalmic Oint 1%	3.5Gm/Tb	Valeant Pharmaceuticals
(121-8942)	Bacitracin Ophthalmic Oint 500u/Gm	1/8oz/Tb	Perrigo Pharmaceuticals
(112-7195)	Bacitracin Zinc/Neo/Poly/HC Ophthalmic Oint	3.5gm/Tb	Henry Schein
(690-0250)	Betadine Ophthalmic Solution 5%	30mL/Bt	Alcon Surgical, Inc.
(332-0002)	BSS Solution 15mL/Bt	15mL/Bt	Alcon Surgical, Inc.
(332-0000)	BSS Solution 500mL/Bt	6/Ca	Alcon Surgical, Inc.
(277-0733)	Ciprofloxacin HCl Ophthalmic Solution 0.3%	2.5mL/Bt	Sandoz Pharmaceuticals
(112-7187)	Ciprofloxacin HCl Ophthalmic Solution 0.3%	5mL/Bt	Henry Schein
(104-8632)	Ciprofloxacin HCl Ophthalmic Solution 0.3%	10mL/Bt	Actavis Pharma (Watson)
(115-6265)	Cyclogyl Ophthalmic Solution 2%	5mL/Bt	Alcon Surgical, Inc.
(119-0147)	Cyclogyl Ophthalmic Solution 2%	15mL/Bt	Alcon Surgical, Inc.
(115-6256)	Cyclomydril Ophthalmic Solution, 0.2%/1%	5mL/Bt	Alcon Surgical, Inc.
(116-1960)	Cyclopentolate HCl Ophth Solution 1%	15mL/Bt	Akorn,Inc.
(121-7755)	Cyclopentolate HCl Ophth Solution 2%	2mL/Bt	Akorn,Inc.
(123-8577)	Cyclopentolate Ophthalmic Solution 1%	2mL/Bt	Valeant Pharmaceuticals
(112-7191)	Erythromycin Ophthalmic Oint 0.5%	3.5gm/Tb	Henry Schein
(245-2955)	Fluorescein (AK-Fluor®) 5ml Vial 10%	12/Pk	Akorn,Inc.
(408-0068)	Fluorescein/Benoxinate Ophth Sol 0.25%/0.4%	5mL/Bt	Altaire Pharmaceuticals
(104-5670)	Fluorescein/Proparacaine Ophth Sol 0.25%/0.5%	5mL/Bt	Altaire Pharmaceuticals
(277-0164)	Flurbiprofen Sodium Ophthalmic Sol 0.03%	2.5mL/Bt	Valeant Pharmaceuticals
(104-3735)	Ful-Glo Ophth Strips 1mg	100/Bx	Akorn,Inc.
(277-0570)	Gentamicin Sulfate Ophthalmc Oint 0.3%	3.5gm/Tb	Akorn,Inc.
(104-9229)	Hydroxypropylene Methyl Ophth Sol 2.5%	15mL	Altaire Pharmaceuticals
(248-0064)	Hylenex (human) SDV, 150u/mL, 1mL	4/Pk	Halozyme Inc
(115-6260)	Iopidine Ophthalmic Solution 0.5%	5mL/Bt	Alcon Surgical, Inc.
(277-0878)	Ketorolac Ophthalmic Solution 0.5%	3mL/Bt	Akorn,Inc.
(123-5465)	Lacri-Lube Ointmnt SOP Ophth Oint	3.5gm/Tb	Allergan Pharm, Inc
(123-4826)	Lacri-Lube Ointmnt SOP Ophth Oint	7gm/Tb	Allergan Pharm, Inc
(228-3444)	Latisse Ophthalmic Solution 0.03%	3mL/Bt	Allergan Pharm, Inc
(245-0058)	Lidocaine (Akten®) Ophthalmic Gel 3.5%	1mL/Bt	Akorn,Inc.
(228-2901)	Maxitrol Ophthalmic Oint	3.5gm/Tb	Alcon Laboratories Inc
(741-0008)	Miochol-E Intraocular Solution Vial 20mg	2mL/Vl	Valeant Pharmaceuticals
(115-6264)	Miostat Intraocular Solution, 0.01%, 1.5mL Vial	12/Pk	Alcon Surgical, Inc.
(119-0143)	Mydriacyl (tropicamide) Ophthalmic Solution 1%	3mL/Bt	Alcon Surgical, Inc.
(119-0144)	Mydriacyl (tropicamide) Ophthalmic Solution 1%	15mL/Bt	Alcon Surgical, Inc.
(122-2073)	Neomycin/Poly-B/Dex Ophthalmic Oint	1/8oz/Tb	Perrigo Pharmaceuticals
(118-0447)	Neomycin/Poly-B/Dex Ophthalmic Susp	5mL/Bt	Valeant Pharmaceuticals
(114-8431)	Neomycin/Poly-B/Gram Ophthalmic Sol	10mL/Bt	Valeant Pharmaceuticals
(112-7189)	Ofloxacin Ophthalmic Solution 0.3%	10mL/Bt	Henry Schein
(106-8913)	Paremyd Ophthalmic Solution 1%/0.25%	15mL/Bt	Akorn,Inc.
(605-0059)	Petroleum Ophthalmic Oint	1/8oz/Tb	Altaire Pharmaceuticals
(121-9849)	Phenylephrine HCl Ophth Solution 2.5%	15mL/Bt	Valeant Pharmaceuticals
(121-9848)	Phenylephrine HCl Ophth Solution 10%	5mL/Bt	Valeant Pharmaceuticals
(111-8933)	Pilocarpine HCL Ophthalmic Solution 1%	15mL/Bt	Falcon Pharmaceuticals
(102-6292)	Pilocarpine HCL Ophthalmic Solution 2%	15mL/Bt	Falcon Pharmaceuticals
(117-3465)	Pilocarpine HCL Ophthalmic Solution 4%	15mL/Bt	Sandoz
(121-1011)	Prednisolone Acetate Ophthalmic Susp 1%	5mL/Bt	Pack Pharmaceuticals
(112-7199)	Proparacaine HCL Ophthalmic Solution 0.5%	15mL/Bt	Henry Schein
(115-6257)	Tetracaine HCl Ophthalmic Solution, 0.5%, 2mL	12/Pk	Alcon Surgical, Inc.
(123-9097)	Tetracaine HCl Ophthalmic Solution 0.5%	15mL/Bt	Altaire Pharmaceuticals
(121-0326)	Timolol Maleate Ophthalmic Solution 0.5%	10mL/Bt	Akorn,Inc.
(228-2945)	Tobradex Ophthalmic Suspension	2.5mL/Bt	Alcon Laboratories Inc
(112-7196)	Tobramycin Ophthalmic Solution 0.3%	5mL/Bt	Henry Schein
(277-0384)	Tobramycin/Dex Ophthalmic Susp, 0.3%/0.1%	2.5mL/Bt	Valeant Pharmaceuticals
(112-7194)	Triple Ophthalmic Ointment	3.5gm/Tb	Henry Schein
(277-0191)	Trimethoprim Sulf/Poly-B Ophth Sol 1mg/10mu/mL	10mL/Bt	Valeant Pharmaceuticals
(124-2479)	Tropicamide Ophthalmic Solution 1%	3mL/Bt	Valeant Pharmaceuticals
(112-7192)	Tropicamide Ophthalmic Solution 1%	15mL/Bt	Henry Schein
(115-6268)	Vigamox Ophthalmic Solution 0.5%	3mL/Bt	Alcon Surgical, Inc.

Abbott Point of Care

An Excellent Choice for Spot Checks for Pre-Screening!

i-STAT® Handheld System

This fully automated system provides accurate results in minutes for a wide range of tests using just 2 or 3 drops of blood.

- Requires no special sample preparation or user calibration; maintenance is minimal
- Easy to use: Insert blood on the cartridge, insert cartridge into the analyzer and view the results in minutes
- Weighs 18 oz, making it portable
- Operator and patient information can be entered via barcode scanner
- Operator lockout prevents unauthorized users from performing or viewing test results
- Test results are uploaded automatically when placed in the downloader

#04J60-20, iSTAT Handheld System
(111-3324) ea
Contains: analyzer, printer, simulator, downloader & manual.

#03P84-25: Creatine, Crea
(111-3394) 25/box

#03P83-25, Glucose: Glu
(111-3393) 25/box

#03P82-25, E3+: Na, K, Hct, Hgb* (*Calculated)
(111-3392) 25/box

#03P81-25, EC4+: Na, K, Glu, Hct, Hgb* (*Calculated)
(111-3391) 25/box

#03P80-25, 6+: Na, K, Cl, BUN/Urea, Glu, Hct, Hgb* (*Calculated)
(111-3390) 25/box

Pregnancy Tests—Results in 10 Minutes
#05P58-25, β-hCG
(982-0021) 25/box

Coagulation Tests—Results in 17 Minutes (PT/INR Results in 5 Minutes)
#03P89-24, PT/INR: Prothrombin Time
(111-3385) 24/box

euflexxa® 1% SODIUM HYALURONATE

FERRING PHARMACEUTICALS

As an authorized Euflexxa® distributor, ALL Henry Schein Physician Customers will receive contract pricing! The MORE you buy, the MORE you SAVE!

No Contract to Sign • No Annual Quantity Commitments!

Euflexxa® Pre-filled Syringe 2 mL, 3/Pk (Jcode*–J7323; Admin Code–20610)

INDICATION: EUFLEXXA® *(1% sodium hyaluronate) is indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen)*

Call your Henry Schein Sales Consultant today for your new pricing!
Reimbursement Hotline:
- The Euflexxa® Reimbursement Hot line is available to assist medical professionals and billing staff who have questions about insurance coverage, claims, or billing
- Call toll-free: **1-866-EUFLEX1** (Monday – Friday, 8:30am – 6:00pm EST)

***For informational purposes only. Source:ReimbursementCodes.com and/or www.cms.gov. Customer is responsible for verification of billing/coding in accordance with applicable specific circumstances.**



Bayer HealthCare

Magnevist Injection

Magnevist (brand of gadopentetate dimeglumine) injection is the N-methylglucamine salt of the gadolinium complex of diethylenetriamine pentaacetic acid, an injectable contrast medium for magnetic resonance imaging (MRI) to be administered by intravenous injection. Each mL contains 469.01 mg gadopentetate dimeglumine, 0.39 mg meglumine, 0.15 mg diethylenetriamine pentaacetic acid and water for injection. A clear, colorless to slightly yellow solution which contains no antimicrobial preservative.

#1973676, 5-mL Vial
(616-0027) 20/case

#1311935, 10-mL Vial
(616-0028) 20/case

#1311745, 15-mL Vial
(616-0029) 20/case

#3218450, 20-mL Vial
(616-0030) 20/case

#1240340, 100-mL Pharmacy Bulk Vial
(616-0013) 10/case

#1213321, 10-mL Prefilled Syringe
(616-0031) 5/pkg

#1213347, 15-mL Prefilled Syringe
(616-0032) 5/pkg

#1213727, 20-mL Prefilled Syringe
(616-0011) 5/pkg

Isovue 200, 41%

#1314-30, 50-mL Glass Vial
(113-4783) 10/box

Isovue-M 200, 41%

#1411-11, 10-mL Vials
(840-6446) 10/box

#1411-25, 20-mL Vials
(840-8206) 10/box

Isovue-250, 51%

#1317-05, 50-mL Vial
(115-6902) 10/case

#1317-02, 100-mL Vial
(115-3175) 10/case

Bayer HealthCare

Ultravist® Injection

Ultravist Injection is available as a stable, ready-to-use aqueous solution of iopromide in vials or bottles in concentrations of 240, 300, and 370 mg iodine per mL. As a proven X-ray contrast medium, Ultravist has a broad range of indications for intra-arterial procedures and intravenous procedures.

Ultravist 240
#342-10, 100-mL Vial
(616-0003) 10/box

#342-21, 200-mL Vial
(616-0025) 10/box

Ultravist 300
#344-05, 50-mL Vial
(616-0004) 10/box

#344-10, 100-mL Vial
(616-0005) 10/box

#344-12, 125-mL Vial
(616-0006) 10/box

#344-15, 150-mL Vial
(616-0007) 10/box

#344-21, 200-mL Pharmacy Bulk Pack
(616-0024) 10/box

#344-58, 500-mL Pharmacy Bulk Pack
(616-0023) 8/box

Ultravist 370
#346-05, 50-mL Vial
(616-0008) 10/box

#346-10, 100-mL Vial
(616-0009) 10/box

#346-15, 150-mL Vial
(616-0022) 10/box

#346-20, 200-mL Vial
(616-0026) 10/box

#346-58, 500-mL Pharmacy Bulk Pack
(616-0010) 8/box

Isovue-M 300, 61%

#1412-15, 15-mL Vial
15 mL
(840-6445) 10/case

Isovue 300, 61%

#1315-25, 30-mL Vial
(110-9291) 10/case

#1315-30, 50-mL Vial
(840-7106) 10/case

#1315-47, 75-mL Bottle
(114-7222) 10/box

#1315-35, 100-mL Bottle
(109-3019) 10/box

#1315-50, 150-mL Bottle
(112-4806) 10/case

Isovue Multipack 300, 61%
#1315-41, 200-mL Bottle
(114-0736) 10/case

#1315-98, 500-mL Bottle
(117-4869) 6/case

Isovue 370, 76%

#1316-30, 50-mL Bottle
(120-4114) 10/box

#1316-52, 75-mL Bottle
(116-9488) 10/box

#1316-35, 100-mL Bottle
(109-3061) 10/box

#1316-04, 125-mL Bottle
(116-0092) 10/box

#1316-37, 150-mL Bottle
(115-3176) 10/box

#1316-41, 200-mL Bottle
(115-6147) 10/box

Isovue Multipack® 370, 76%
#1316-98, 500-mL Bottle
(840-9716) 6/case

ProHance® Contrast Medium

ProHance® (gadoteridol) is a contrast medium for magnetic resonance imaging (MRI) in the form of a sterile, apyrogenic solution for intravenous injection. In MRI, ProHance® provides contrast enhancement of the brain, spine and surrounding tissues, resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood-brain barrier. ProHance® can also be used for whole-body MRI, including the head, neck, liver, breast, musculoskeletal system, and soft tissue pathologies.

#1111-04, 5-mL SDV
(113-2005) 5/box

#1111-01, 10-mL SDV
(113-2003) 5/box

#1111-02, 15-mL SDV
(113-2006) 5/box

#1111-03, 20-mL SDV
(113-2002) 5/box

#1111-70, 50-mL Multipack
(113-2036) 5/box

#1111-16, 10-mL Prefilled Syringe
(113-1998) 5/box

#1111-45, 17-mL Prefilled Syringe
(111-9432) 5/box

Mallinckrodt Pharmaceuticals

Optimark

#1177-04, 10-mL Vial
(748-0053) 10/case

#1177-06, 15-mL Vial
(748-0037) 10/case

#1177-02, 5-mL Vial
(748-0080) 10/case

#1177-08, 20-mL Vial
(748-0021) 10/case

#1177-50, 50-mL Vial
(748-0043) 5/case

#1177-11, 10-mL Prefilled Syringe
(748-0120) 10/box

#1177-16, 15-mL Prefilled Syringe
(748-0122) 10/box

#1177-21, 20-mL Prefilled Syringe
(748-0121) 10/box

#1177-31, 30-mL Prefilled Syringe
(748-0123) 10/box

Mallinckrodt Pharmaceuticals

Optiray™ 300 Injectable Contrast Agent

Optiray™ 300 contrast agent is a non-ionic, low osmolar, lower viscosity injectable and intended for intravascular administration. It is a prescription drug that is intended to be therapeutically and biologically inert when injected into the body for use in organ or tissue enhancement in CT, X-ray and fluoroscopy imaging procedures for which it is approved. Each mL of Optiray™ 300 contrast agent contains 636 mg of ioversol, 3.6 mg of tromethamine as a buffer and 0.2 mg of edetate calcium disodium as a stabilizer.

#1332-06, 50-mL Bottle
(748-0054) 25/case

#1332-11, 100-mL Bottle
(748-0020) 12/case

#1332-16, 150-mL Bottle
(748-0026) 12/case

#1332-21, 200-mL Bottle
(748-0077) 12/box

#1332-78, 50-mL Ultraject™ Prefilled Handheld Syringe
(748-0126) 20/box

#1332-83, 100-mL Ultraject™ Prefilled Power Injector
(748-0011) 20/case

#1332-00, 100-mL Ultraject™ Prefilled RFID Power Injector
(748-0071) 20/box

#1332-61, 500-mL Bottle, Multidose Pharmacy Bulk Package
(748-0031) 6/box

GE imagination at work

Omnipaque™ Contrast Media

A low osmolar, nonionic, iodinated contrast agent. Its indications include a broad range of intravascular diagnostic procedures such as a coronary angiography, spinal cord imaging, and body cavity procedures including shoulder and knee joints. Omnipaque is approved for use in adults and children, and is available in a variety of packagings.

#Y-101, 180 mg, 10-mL Vial
(638-9526) 10/box

#Y-102, 180 mg, 20-mL Vial
(393-2273) 10/box

#Y-203, 240 mg, 10-mL Vial
(638-2431) 10/box

#Y-220, 240 mg, 20-mL Vial
(600-4244) 10/box

#Y-306, 300 mg, 10-mL Vial
(931-4685) 10/box

#Y-503, 300 mg, 30-mL Vial
(116-7608) 10/box

#Y-520, 240 mg, 50-mL Polymer Bottle
(108-9526) 10/box

#Y-530, 300 mg, 50-mL Polymer Bottle
(108-5540) 10/box

#Y-540, 350 mg, 50-mL Polymer Bottle
(108-5551) 10/box

#Y-524, 240 mg, 150-mL Polymer Bottle
(106-2767) 10/box

#Y-531, 300 mg, 75-mL Polymer Bottle
(114-8309) 10/box

#Y-532, 300 mg, 100-mL Polymer Bottle
(114-9045) 10/box

#Y-534, 300 mg, 150-mL Polymer Bottle
(114-9048) 10/box

#Y-542, 350 mg, 100-mL Polymer Bottle
(112-4076) 10/box

#Y-544, 350 mg, 150-mL Polymer Bottle
(118-2416) 10/box

NEW!

Vanilla SilQ™ Barium Sulfate Suspension
450 mL
(124-1098) 24/case

FlavorSelect Foil Pouch, 5 mL

For use with Vanilla SilQ™ barium sulfate suspension.

FlavorSelect 24/pkg

Specify:
Orange ..... **(124-2160)**
Berry ..... **(124-2161)**
Banana ..... **(124-2162)**

GE imagination at work

Omniscan (Gadodiamide) Injection

Omniscan Injection is the formulation of the gadolinium complex of diethylenetriamine pentaacetic acid bismethylamide, an injectable, nonionic extracellular enhancing agent for magnetic resonance imaging, administered by intravenous injection. Provided as a sterile, clear to slightly yellow, aqueous solution. Each mL contains 287 mg gadodiamide, 12 mg caldiamide sodium, and water for injection.

#J-068, 5-mL Vial
(115-9513) 10/box

#J-100, 10-mL Vial
(104-8590) 10/box

#J-120, 15-mL Fill in 20-mL Vial
(600-8007) 10/box

#J-140, 20-mL Vial
(381-9006) 10/box

#J-160, 10-mL Prefilled Syringe
(605-0209) 10/box

#J-170, 15-mL Prefilled Syringe
(673-9006) 10/box

#J-800, 100-mL PlusPak Polymer Bottle
(114-0840) 10/box

GE imagination at work

Visipaque Contrast Media

Of all the iodine concentrations, this is the only iso-osmolar contrast medium available for intravascular use. It is indicated for Contrast Enhanced Computer Tomography (CECT) imaging of the head and body.

Visipaque 270
270 mg/mL
#V026, 150-mL Bottle
(638-0002) 10/box

#V552, 100-mL Bottle
(106-3773) 10/box

Visipaque 320
320 mg/mL
#V560, 50-mL Bottle
(121-3875) 10/box

#V-562, 100-mL Bottle
(119-7345) 10/box

#V564, 150-mL PlusPak
(118-2491) 10/box

#V568B, 500-mL PlusPak Bulk
(116-6175) 10/box

CONSIDER DYLOJECT AS YOUR NON-OPIOID IV ANALGESIC OPTION

Dyloject
(DICLOFENAC SODIUM)
INJECTION 37.5 mg/mL

DYLOJECT is indicated in adults for the management of[1]:

- Mild to moderate pain
- Moderate to severe pain alone or in combination with opioid analgesics

In 2 pivotal clinical trials, DYLOJECT was proven effective in post-operative patients with moderate to severe pain:

- Efficacy was demonstrated by a reduction in pain intensity as measured by the sum of the pain intensity differences over 0 to 48 hours in patients receiving DYLOJECT as compared to placebo[1*]
- 26% and 37% post-operative patients administered DYLOJECT did not receive opioids in the first 48 hours[1]

DYLOJECT administration:

- Bolus injection in 15 seconds[1]
- No dilution required[1]
- To reduce the risk of renal adverse reactions, patients must be well hydrated prior to administering DYLOJECT[1]

DYLOJECT offers:

- Reaches C_{max} in 5 minutes[1]
- Achieves C_{max} 5-7x oral immediate release diclofenac[1]

*Data from 2 randomized, controlled, multiple-dose studies of adult patients who had undergone elective orthopedic surgery (Study 1; N=277) or elective abdominal or pelvic surgery (Study 2; N=345) administered DYLOJECT, a positive NSAID control (ketorolac tromethamine), or placebo every 6 hours starting within 6 hours post-surgery and for up to 5 days. Rescue IV morphine was available upon patient request.

Important Safety Information

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

Cardiovascular Risk

- **Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.**
- **DYLOJECT is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.**

Gastrointestinal Risk

- **NSAIDs increase the risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events.**

Contraindications

- DYLOJECT is contraindicated in patients with:
  - Known hypersensitivity to diclofenac.
  - History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
  - Perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
  - Moderate to severe renal insufficiency in the perioperative period and who are at risk for volume depletion.

Warnings and Precautions

- Serious and potentially fatal cardiovascular (CV) thrombotic events, myocardial infarction, and stroke: Patients with known CV disease or risk factors for CV disease may be at greater risk. Use for the shortest possible duration.
- Serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation, which can be fatal. Use for the shortest possible duration. Use with caution in patients with prior history of ulcer disease or GI bleeding.
- Renal papillary necrosis and other renal injury with long-term administration of NSAIDs: Use caution when initiating treatment with DYLOJECT in patients with considerable dehydration. DYLOJECT is not recommended in patients with moderate to severe renal insufficiency. Use DYLOJECT with caution in patients at greatest risk for this reaction, including the elderly; those with impaired renal function, heart failure, or liver impairment; and those taking diuretics or ACE inhibitors.
- Elevation of one or more liver tests and severe hepatic reactions: To minimize the potential risk for an adverse liver-related event in patients treated with diclofenac, use for the shortest duration possible. Exercise caution when prescribing DYLOJECT with concomitant drugs that are known to be potentially hepatotoxic (e.g., acetaminophen, certain antibiotics, anti-epileptics). Discontinue DYLOJECT immediately if abnormal liver tests persist or worsen.
- New onset or worsening of hypertension: NSAIDs, including DYLOJECT, can lead to onset of new hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of CV events. Monitor blood pressure closely during treatment with DYLOJECT.
- Fluid retention and edema: Use DYLOJECT with caution in patients with fluid retention or heart failure.
- Anaphylactic reactions in patients with the aspirin triad or in patients without prior exposure to DYLOJECT: Discontinue DYLOJECT immediately if an anaphylactic reaction occurs.
- Serious skin reactions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. Discontinue DYLOJECT if rash or other signs of local skin reaction occur.
- Starting at 30 weeks gestation, DYLOJECT and other NSAIDs, should be avoided by pregnant women as premature closure of the ductus arteriosus in the fetus may occur. If this drug is used during this time period in pregnancy, the patient should be apprised of the potential hazard to a fetus.
- Clinical studies and postmarketing observations have shown that DYLOJECT can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, observe patients closely for signs of renal failure, as well as to assure diuretic efficacy.

Adverse Reactions

- The most common adverse reactions (>5%) in controlled clinical trials include nausea, constipation, headache, infusion site pain, dizziness, flatulence, vomiting, and insomnia.

Please see Brief Summary, including BOXED WARNING, on following pages.

References: 1. DYLOJECT [package insert]. Lake Forest, IL: Hospira, Inc; December 2014. **2.** Hospira, Inc. Data on file. Pharmacokinetic report: Intravenous diclofenac sodium versus oral diclofenac potassium (Cataflam). 2007.

BRIEF SUMMARY OF PRESCRIBING INFORMATION

Dyloject™

(diclofenac sodium) Injection, for intravenous use

Rx Only

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

Cardiovascular Risk

- **Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.**
- **Dyloject is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.**

Gastrointestinal Risk

- **NSAIDs increase the risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events.**

INDICATIONS AND USAGE

Dyloject is an NSAID indicated in adults for the management of mild to moderate pain and management of moderate to severe pain alone or in combination with opioid analgesics.

CONTRAINDICATIONS

Dyloject is contraindicated in patients with:

- known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac.
- a history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal anaphylactic-like reactions to NSAIDs have been reported in such patients.
- perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
- moderate to severe renal insufficiency in the perioperative period and who are at risk for volume depletion.

WARNINGS AND PRECAUTIONS

Cardiovascular Thrombotic Events

Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, myocardial infarction and stroke, which can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with an NSAID, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. Patients should be informed about the signs and/or symptoms of serious CV events and the steps to take if they occur.

Two large, controlled clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10-14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.

There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID does increase the risk of serious gastrointestinal (GI) events.

Gastrointestinal Effects: Risk of Ulceration, Bleeding, and Perforation

NSAIDs, including Dyloject, can cause serious GI adverse events including inflammation, bleeding, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3-6 months and in about 2-4% of patients treated for one year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. Dyloject is administered by intravenous injection and is intended for acute short term use. However, even short-term therapy is not without risk.

Prescribe NSAIDs, including Dyloject, with extreme caution in those with a prior history of ulcer disease or GI bleeding. Patients with a prior history of peptic ulcer disease and/or GI bleeding who use NSAIDs have a greater than 10-fold increased risk for developing a GI bleed compared to treated patients with neither of these risk factors. Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. Most reports of spontaneous fatal GI events are in elderly or debilitated patients, and therefore special care should be taken in treating this population.

To minimize the potential risk for an adverse GI event in patients treated with an NSAID, use the lowest effective dose for the shortest possible duration. Patients and physicians should remain alert for signs and symptoms of GI ulcerations and bleeding during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI event is suspected. This should include discontinuation of the NSAID until a serious GI adverse event is ruled out. For high-risk patients, alternate therapies that do not involve NSAIDs should be considered.

Renal Effects

Use caution when initiating treatment with Dyloject in patients with considerable dehydration. Dyloject is not recommended in patients with moderate to severe renal insufficiency and is contraindicated in patients with moderate to severe renal insufficiency in the perioperative period and who are at risk for volume depletion. Acute renal decompensation was observed in 4% out of 68 patients enrolled with renal impairment and treated with Dyloject in clinical trials in the perioperative period.

Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

Hepatic Effects

Elevations of one or more liver tests may occur during therapy with Dyloject. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continued therapy. Borderline elevations (i.e., less than 3 times the ULN [ULN = the upper limit of the normal range]) or greater elevations of transaminases occurred in about 15% of diclofenac-treated patients in clinical trials of indications other than acute pain. Of the markers of hepatic function, ALT (SGPT) is recommended for the monitoring of liver injury.

In clinical trials of oral diclofenac, meaningful elevations (i.e., more than 3 times the ULN) of AST (SGOT) occurred in about 2% of approximately 5,700 patients at some time during diclofenac treatment (ALT was not measured in all studies).

In a large, open-label, controlled trial of 3,700 patients treated for 2-6 months, patients were monitored first at 8 weeks and 1,200 patients were monitored again at 24 weeks. Meaningful elevations of ALT and/or AST occurred in about 4% of the 3,700 patients and included marked elevations (i.e., more than 8 times the ULN) in about 1% of the 3,700 patients. In this open-label study, a higher incidence of borderline (less than 3 times the ULN), moderate (3-8 times the ULN), and marked (greater than 8 times the ULN) elevations of ALT or AST was observed in patients receiving diclofenac when compared to other NSAIDs. Elevations in transaminases were seen more frequently in patients with osteoarthritis than in those with rheumatoid arthritis. Almost all meaningful elevations in transaminases were detected before patients became symptomatic. Abnormal tests occurred during the first 2 months of therapy with diclofenac in 42 of the 51 patients in all trials who developed marked transaminase elevations.

In postmarketing reports, cases of drug-induced hepatotoxicity have been reported in the first month, and in some cases, the first 2 months of therapy, but can occur at any time during treatment with diclofenac. Postmarketing surveillance has reported cases of severe hepatic reactions, including liver necrosis, jaundice, fulminant hepatitis with and without jaundice, and liver failure. Some of these reported cases resulted in fatalities or liver transplantation.

Measure transaminases (ALT and AST) periodically in patients receiving long-term therapy with diclofenac, because severe hepatotoxicity may develop without a prodrome of distinguishing symptoms. The optimum times for making the first and subsequent transaminase measurements are not known. Based on clinical trial data and postmarketing experiences, transaminases should be monitored within 4 to 8 weeks after initiating treatment with diclofenac. Dyloject is not indicated for long-term treatment. However, severe hepatic reactions can occur at any time during treatment with diclofenac.

If abnormal liver tests persist or worsen, if clinical signs and/or symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g. eosinophilia, rash, abdominal pain, diarrhea, dark urine, etc.), discontinue Dyloject immediately. To minimize the possibility that hepatic injury will become severe between transaminase measurements, inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms), and the appropriate action patients should take if these signs and symptoms appear. To minimize the potential risk for an adverse liver-related event in patients treated with diclofenac, use the lowest effective dose for the shortest duration possible. Exercise caution when prescribing Dyloject with concomitant drugs that are known to be potentially hepatotoxic (e.g., acetaminophen, certain antibiotics, anti-epileptics).

Hypertension

NSAIDs, including Dyloject, can lead to onset of new hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of CV events. Use NSAIDs, including Dyloject, with caution in patients with hypertension. Monitor blood pressure closely during the initiation of NSAID treatment and throughout the course of therapy.

Patients taking ACE inhibitors, thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs.

Congestive Heart Failure and Edema

Fluid retention and edema have been observed in some patients taking NSAIDs. Use Dyloject with caution in patients with fluid retention or heart failure.

Anaphylactic Reactions

As with other NSAIDs, anaphylactic reactions may occur in patients without known prior exposure to Dyloject. Dyloject is contraindicated in patients with the aspirin triad. This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs.

Serious Skin Reactions

NSAIDs, including Dyloject, can cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events may occur without warning. Inform patients about the signs and symptoms of serious skin manifestations, and discontinue Dyloject at the first appearance of skin rash or any other sign of hypersensitivity.

Pregnancy

Starting at 30 weeks gestation, Dyloject and other NSAIDs, should be avoided by pregnant women as premature closure of the ductus arteriosus in the fetus may occur. If this drug is used during this time period in pregnancy, the patient should be apprised of the potential hazard to a fetus.

Corticosteroid Treatment

Dyloject cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to exacerbation of corticosteroid-responsive illness. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids.

Masking Inflammation and Fever

The pharmacological activity of Dyloject in reducing inflammation, and possibly fever, may diminish the utility of these diagnostic signs in detecting infectious complications of presumed noninfectious, painful conditions.

Hematological Effects

Anemia may occur in patients receiving NSAIDs, including Dyloject. This may be due to fluid retention, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. In patients on long-term treatment with NSAIDs, including diclofenac, check hemoglobin or hematocrit if they exhibit any signs or symptoms of anemia or blood loss. Dyloject is not indicated for long-term treatment.

NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Carefully monitor patients who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants.

Pre-existing Asthma

Patients with asthma may have aspirin-sensitive asthma. The use of aspirin in patients with aspirin-sensitive asthma has been associated with severe bronchospasm, which can be fatal. Since cross-reactivity between aspirin and NSAIDs has been reported in such aspirin-sensitive patients, including bronchospasm, Dyloject is contraindicated in patients with this form of aspirin sensitivity and should be used with caution in all patients with pre-existing asthma.

Monitoring

Because serious GI tract ulcerations and bleeding can occur without warning symptoms, monitor for signs or symptoms of GI bleeding.

For patients on long-term treatment with NSAIDs, periodically check a CBC and chemistry profile, including liver function tests. Discontinue Dyloject if clinical signs and symptoms consistent with liver or renal disease develop, systemic manifestations occur (e.g., eosinophilia, rash), or abnormal liver tests persist or worsen. Dyloject is not indicated for long-term treatment.

ADVERSE REACTIONS

The following serious adverse reactions are discussed elsewhere in the labeling:

- Cardiovascular thrombotic events
- Gastrointestinal effects
- Renal effects
- Hepatic effects
- Hypertension
- Congestive heart failure and edema
- Anaphylactoid reactions
- Serious skin reactions

Adverse reactions from clinical studies of Dyloject

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

During clinical development, 1,156 patients were exposed to Dyloject in multiple-dose, controlled and open-label studies. Dyloject was administered post-surgically every 6 hours for up to 5 days. The incidence rates of adverse reactions listed in the following table are derived from multicenter, controlled clinical studies in post-operative patients comparing Dyloject to placebo in patients who may have also received morphine rescue medication.

Table 1: Proportion of Patients Experiencing Common Adverse Reactions in Placebo-Controlled Clinical Studies in Patients with Acute Moderate-to-Severe Postoperative Pain occurring in greater than or equal to 3% in patients treated with Dyloject*

MedDRA Preferred Term	Placebo N=126	Dyloject N=187
Any Reaction	104 (83%)	146 (78%)
Nausea	50 (40%)	45 (24%)
Constipation	14 (11%)	25 (13%)
Headache	20 (16%)	19 (10%)
Infusion Site Pain	10 (8%)	19 (10%)
Dizziness	2 (2%)	15 (8%)
Flatulence	20 (16%)	15 (8%)
Vomiting	23 (18%)	12 (6%)
Insomnia	12 (10%)	11 (6%)
Pruritus	10 (8%)	9 (5%)
Hypotension	6 (5%)	9 (5%)
Pyrexia	13 (10%)	8 (4%)
Anemia	9 (7%)	8 (4%)
Infusion Site Extravasation	1 (1%)	6 (3%)

* Intravenous morphine was permitted as rescue medication for pain management.

Adverse reactions from clinical studies or spontaneous reports for other formulations of diclofenac and other NSAIDs

In patients taking diclofenac or other NSAIDs, the most frequently reported adverse reactions occurring in approximately 1%-10% of patients are:

Gastrointestinal experiences including abdominal pain, constipation, diarrhea, dyspepsia, flatulence, gross bleeding/perforation, heartburn, nausea, GI ulcers (gastric/duodenal) and vomiting.

Abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, headaches, increased bleeding time, pruritus, rashes and tinnitus.

Additional adverse reactions reported occasionally include:

Body as a Whole: fever, infection, sepsis

Cardiovascular System: congestive heart failure, hypertension, tachycardia, syncope

Digestive System: esophagitis, gastric/peptic ulcers, gastritis, gastrointestinal bleeding, glositis, hematemesis, hepatitis, jaundice

Hemic and Lymphatic System: ecchymosis, eosinophilia, leukopenia, melena, purpura, rectal bleeding, stomatitis, thrombocytopenia

Metabolic and Nutritional: weight changes

Nervous System: anxiety, asthenia, confusion, depression, dream abnormalities, drowsiness, insomnia, malaise, nervousness, paresthesia, somnolence, tremors, vertigo

Respiratory System: asthma, dyspnea

Skin and Appendages: alopecia, photosensitivity, sweating increased

Special Senses: blurred vision

Urogenital System: cystitis, dysuria, hematuria, interstitial nephritis, oliguria/polyuria, proteinuria, renal failure

Other adverse reactions, which occur rarely are:

Body as a Whole: anaphylactic reactions, appetite changes, death

Cardiovascular System: arrhythmia, hypotension, myocardial infarction, palpitations, vasculitis

Digestive System: colitis, eructation, fulminant hepatitis with and without jaundice, liver failure, liver necrosis, pancreatitis

Hemic and Lymphatic System: agranulocytosis, hemolytic anemia, aplastic anemia, lymphadenopathy, pancytopenia

Metabolic and Nutritional: hyperglycemia

Nervous System: convulsions, coma, hallucinations, meningitis

Respiratory System: respiratory depression, pneumonia

Skin and Appendages: angioedema, toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, urticaria

Special Senses: conjunctivitis, hearing impairment

Adverse reactions of special interest

Based on the analysis of the pooled data from the multi-dose, controlled clinical trials, post-operative patients treated with Dyloject had more adverse reactions related to wound healing (7.5%) compared to patients treated with placebo (4%).

DRUG INTERACTIONS

Aspirin

When administered with aspirin, the protein binding of Dyloject is reduced. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of Dyloject and aspirin is not generally recommended because of the potential of increased adverse effects.

Anticoagulants

The effects of anticoagulants (e.g., warfarin) and NSAIDs on GI bleeding are synergistic, such that the users of both drugs together have a higher risk of serious GI bleeding than users of either drug alone.

ACE Inhibitors

NSAIDs may diminish the antihypertensive effect of ACE inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.

Cyclosporine

NSAIDs, including Dyloject, may affect renal prostaglandins and increase the toxicity of certain drugs. Therefore, concomitant therapy with Dyloject may increase cyclosporine's nephrotoxicity. Use caution when Dyloject is administered concomitantly with cyclosporine.

Diuretics

Clinical studies and postmarketing observations have shown that Dyloject can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, observe patients closely for signs of renal failure, as well as to assure diuretic efficacy.

Lithium

NSAIDs have produced elevations of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance decreased by 20%. This effect has been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, when NSAIDs and lithium are administered concurrently, observe patients carefully for signs of lithium toxicity.

Methotrexate

NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This indicates that NSAIDs may enhance the toxicity of methotrexate. Use caution when NSAIDs are administered concomitantly with methotrexate.

CYP2C9 Inhibitors or Inducers

Diclofenac is metabolized by cytochrome P450 enzymes, predominantly by CYP2C9. Co-administration of diclofenac with CYP2C9 inhibitors (e.g. voriconazole) may enhance the exposure and toxicity of diclofenac whereas co-administration with CYP2C9 inducers (e.g. rifampin) may lead to compromised efficacy of diclofenac. Use caution when dosing Dyloject with CYP2C9 inhibitors or inducers; a dosage adjustment may be warranted.

USE IN SPECIFIC POPULATIONS

Pregnancy

Teratogenic Effects - Pregnancy Category C prior to 30 weeks gestation; Category D starting at 30 weeks gestation.

Starting at 30 weeks gestation, Dyloject and other NSAIDs should be avoided by pregnant women as premature closure of the ductus arteriosus in the fetus may occur. Dyloject can cause fetal harm when administered to a pregnant woman starting at 30 weeks gestation.

There are no adequate and well-controlled studies in pregnant women. Prior to 30 weeks gestation, Dyloject should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Reproductive studies have been performed in mice given diclofenac sodium (up to 20 mg/kg/day or 60 mg/m^2/day) and in rats and rabbits given diclofenac sodium (up to 10 mg/kg/day or 60 mg/m^2/day for rats, and 80 mg/m^2/day for rabbits, 0.75-fold and 1-fold the maximum recommended human dose (MRHD) of 150 mg/day based on body surface area comparison, respectively), and have revealed no evidence of teratogenicity despite the induction of maternal toxicity and fetal toxicity. In rats maternally toxic doses were associated with dystocia, prolonged gestation, reduced fetal weights and growth, and reduced fetal survival. Diclofenac has been shown to cross the placental barrier in mice, rats, and humans.

Labor and Delivery

Dyloject should not be used in labor and delivery due to the inhibitory effects on prostaglandin synthesis that may adversely affect fetal circulation, inhibit uterine contractions and increase risk of uterine bleeding.

In rat studies, maternal exposure to NSAIDs, as with other drugs known to inhibit prostaglandin synthesis, increased the incidence of dystocia and delayed parturition, and decreased pup survival.

Nursing Mothers

Based on available data, diclofenac may be present in human milk. One woman treated orally with a diclofenac salt, 150 mg/day, had a milk diclofenac level of 100 mcg/L, equivalent to an infant dose of about 0.03 mg/kg/day. Diclofenac was not detectable in breast milk in 12 women using diclofenac (after either 100 mg/day orally for 7 days or a single 50 mg intramuscular dose administered in the immediate postpartum period). Exercise caution when Dyloject is administered to a nursing woman.

Pediatric Use

The safety and efficacy of Dyloject have not been established in pediatric patients.

Geriatric Use

Use caution in elderly patients given the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Diclofenac metabolites are known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, use caution in this patient population, and it may be useful to monitor renal function.

Elderly patients are at increased risk for serious GI and renal adverse events. Older age increases the risk for GI bleeding. Most spontaneous reports of fatal GI events are in elderly or debilitated patients, and therefore special care should be taken in treating this population.

The pharmacokinetics of Dyloject are similar in elderly compared to young adults.

Hepatic Impairment

Orally administered diclofenac sodium is extensively metabolized. The pharmacokinetics of Dyloject are similar in patients with mild hepatic impairment compared to healthy subjects. Dosing adjustments in patients with mild hepatic impairment is not necessary. The pharmacokinetics of Dyloject were not studied in patients with moderate to severe hepatic impairment and use in this population is not recommended.

Renal Impairment

Pharmacokinetics of Dyloject in patients with mild to moderate renal impairment is similar compared to healthy subjects. However, acute renal decompensation was observed in 4% out of 68 patients enrolled with renal impairment and treated with Dyloject in clinical trials in the perioperative period. Dyloject is not recommended in patients with moderate to severe renal insufficiency and is contraindicated in patients with moderate to severe renal insufficiency in the perioperative period and who are at risk for volume depletion.

Body Weight

Pharmacokinetics of diclofenac following Dyloject injection appear to be dependent on body weight. The effect of body weight on clinical efficacy and safety of Dyloject has not been fully studied. Therefore, adjusting dose based on body weight is not recommended.

OVERDOSAGE

Symptoms following acute NSAID overdoses are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression and coma may occur, but are rare. Anaphylactoid reactions have been reported with therapeutic ingestion of NSAIDs, and may occur following an overdose.

Patients should be managed by symptomatic and supportive care following an NSAID overdose. There are no specific antidotes. Forced diuresis, alkalinization of urine, hemodialysis, or hemoperfusion may be employed but are not likely to be useful due to high protein binding. In case of an overdosage, discontinue Dyloject therapy and consider contacting a regional poison control center at 1-800-222-1222.

Adapted from: EN-3738; Revised 12/2014

Manufactured for:
Hospira, Inc., Lake Forest, IL 60045 USA

HENRY SCHEIN®
DxRxSolutions™
DIAGNOSE • TREAT • PREVENT

About Henry Schein DxRx Solutions

What is Henry Schein DxRx Solutions?

Henry Schein DxRx Solutions is a collection of resources provided free of charge to our loyal Henry Schein customers with a mission to assist health care practitioners with answers and practical solutions regarding the diagnosis, treatment, and prevention of disease.

Henry Schein DxRx Hotline

The Henry Schein DxRx Hotline is a resource to assist medical professionals with various types of questions on diagnostics, pharmaceuticals, and vaccines that are purchased from Henry Schein. The hotline provides information on the following topics for diagnostics, pharmaceuticals, and vaccines:

- *Indications and usage as provided on a package insert*
- *Package inserts*
- *Brand to generic comparisons*
- *CPT Codes and J Codes**
- *Latest updates on supply issues*

The Henry Schein DxRx Hotline can be reached Monday – Friday, 8:30AM to 5:00PM EST at **1-877-523-SHOT** (7468), via E-mail at DxRxSolutions@henryschein.com, or via live chat with a representative on our Web site, www.henryschein.com/dxrxsolutions.

**For informational purposes only. Source: www.ReimbursementCodes.com and/or www.cms.gov*
Customer is responsible for verification of billing/coding in accordance with applicable specific circumstances.

Call
1-800-P-SCHEIN
(1-800-772-4346)
8am–8:30pm (et)

Fax:
1-800-329-9109
24 Hours

www.henryschein.com

Due to manufacturer price increases, prices are subject to change without notification. Offer valid on our full array of products. Upon any request by Medicare, Medicaid, Tricare or other payer, you must report the value of any benefit received from a discount program (e.g., points redemptions, gifts or other special awards). ©2016 Henry Schein, Inc. No copying without permission. Not responsible for typographical errors. No adjustments from prior sales. Offer not to be combined with other promotions and/or special contract pricing. Void where prohibited. Local regulatory requirements may apply to use or installation of certain products. It is your responsibility to understand and comply with any such requirements prior to purchase, use or installation of products. †For informational purposes only. Source: ReimbursementCodes.com and/or www.cms.gov. Customer is responsible for verification of billing/coding in accordance with applicable specific circumstances.

15MS4848

Printed on recycled paper.
Please recycle it again.

HENRY SCHEIN®
Henry Schein, Inc. • 135 Duryea Road • Melville, NY 11747

PRSRT STD
U.S. POSTAGE
PAID
HENRY SCHEIN, INC.